<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:CPEQU="http://CPEQU/20220331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_CPEQU_CPEQU_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001873964 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DCurrentFiscalYearEndDate_12/31 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityCentralIndexKey">0001873964</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate">12/31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" id="xdx2ixbrl0056" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0059" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0062" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0065" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2022-03-31" id="xdx2ixbrl0067" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0071" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2022-03-31" id="xdx2ixbrl0085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:DeferredUnderwritersDiscount" contextRef="AsOf2021-12-31" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockRedemptionAmount" contextRef="AsOf2021-12-31" id="xdx2ixbrl0101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-03-31" id="xdx2ixbrl0114" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31_custom_ClassAOrdinarySharesMember" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-03-31" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_ClassAOrdinarySharesMember617413109" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_ClassAOrdinarySharesMember617413109" id="xdx2ixbrl0211" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:SaleOf471875PrivateUnitsNetOfAllocatedOfferingCosts" contextRef="From2022-01-012022-03-31_custom_ClassBOrdinarySharesMember" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:SaleOf471875PrivateUnitsNetOfAllocatedOfferingCosts" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:FairValueOf4312500publicWarrantsNetOfAllocatedOfferingCosts" contextRef="From2022-01-012022-03-31_custom_ClassAOrdinarySharesMember" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:FairValueOf4312500publicWarrantsNetOfAllocatedOfferingCosts" contextRef="From2022-01-012022-03-31_custom_ClassBOrdinarySharesMember" id="xdx2ixbrl0224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:FairValueOf4312500publicWarrantsNetOfAllocatedOfferingCosts" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:IssuanceOf38750UnderwriterFounderShares" contextRef="From2022-01-012022-03-31_custom_ClassBOrdinarySharesMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:IssuanceOf38750UnderwriterFounderShares" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-012022-03-31_custom_ClassAOrdinarySharesMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CPEQU:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-012022-03-31_custom_ClassBOrdinarySharesMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_custom_ClassAOrdinarySharesMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_custom_ClassBOrdinarySharesMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2022-01-012022-03-31_custom_NonRedeemableMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cpequ-20220331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CPEQU:UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_ClassOrdinarySharesParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CPEQU:ClassOrdinarySharesParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RedeemableWarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CPEQU:RedeemableWarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-13_custom_ClassAOrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CPEQU:ClassAOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-13_custom_ClassBOrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CPEQU:ClassBOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ClassAOrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CPEQU:ClassAOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ClassAOrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CPEQU:ClassAOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ClassBOrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CPEQU:ClassBOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ClassBOrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CPEQU:ClassBOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ClassAOrdinarySharesMember617413109">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CPEQU:ClassAOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ClassBOrdinarySharesMember617413109">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CPEQU:ClassBOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_ClassAOrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CPEQU:ClassAOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_ClassBOrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CPEQU:ClassBOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ClassAOrdinarySharesMember617413125">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CPEQU:ClassAOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ClassBOrdinarySharesMember617413125">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CPEQU:ClassBOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-11_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-11_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-11_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012021-02-11_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2021-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_UnsecuredPromissoryNoteMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CPEQU:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CPEQU:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RedeemableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CPEQU:RedeemableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_NonRedeemableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CPEQU:NonRedeemableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_PrivatePlacementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CPEQU:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_PrivatePlacementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CPEQU:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CPEQU:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-23_custom_SponsorMember_custom_OtherFounderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CPEQU:SponsorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">CPEQU:OtherFounderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CPEQU:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">CPEQU:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_AdministrativeSupportAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CPEQU:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">CPEQU:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-11_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">CPEQU:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">CPEQU:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CPEQU:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PrivatePlacementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001873964</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CPEQU:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">UNITED
STATES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#160;SECURITIES
AND EXCHANGE COMMISSION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">Washington,
D.C. 20549</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>FORM <span id="xdx_908_edei--DocumentType_c20220101__20220331_zRkA7l1zJU77"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#160;&#160;<span id="xdx_90A_edei--DocumentQuarterlyReport_c20220101__20220331_zunCSmNVksD8"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>&#160;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the quarterly period ended <span id="xdx_906_edei--DocumentPeriodEndDate_c20220101__20220331_zuTCblyGt0x"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, 2022</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#160;&#160;&#160;<span id="xdx_900_edei--DocumentTransitionReport_c20220101__20220331_zWjcWq2OBmSk"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the transition period from ___________ to
___________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commission file number: <b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityFileNumber_c20220101__20220331_zo7UAODzvgke"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityFileNumber">001-41274</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20220101__20220331_zvMNZv5OWR5j"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityRegistrantName">Counter Press Acquisition Corporation</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b>(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; width: 50%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20220101__20220331_zFvI12i2Lh5j"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Cayman Islands</ix:nonNumeric></span></b></span></td>
<td style="width: 2%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 48%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A <span id="xdx_908_edei--EntityTaxIdentificationNumber_c20220101__20220331_zDlqRvtXNKz" style="display: none"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityTaxIdentificationNumber">00-0000000</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
or other jurisdiction of<br /> incorporation or organization)</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
Employer<br /> Identification No.)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20220101__20220331_zT1WEk5azUB2"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine1">1981 Marcus Avenue</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20220101__20220331_zYwRMPJXTUyd"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine2">Suite 227</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;<b><span id="xdx_902_edei--EntityAddressCityOrTown_c20220101__20220331_zlRoRRdSFBD5"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressCityOrTown">Lake Success</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20220101__20220331_z3q0P6uJuHj5"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressPostalZipCode_c20220101__20220331_zcLOqx5hYN34"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressPostalZipCode">11042</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90E_edei--CityAreaCode_c20220101__20220331_zQDMU2mpj3uj"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:CityAreaCode">(718)</ix:nonNumeric></span> <span id="xdx_906_edei--LocalPhoneNumber_c20220101__20220331_z1BpRmQoWKdf"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:LocalPhoneNumber">775-3013</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b>(Former name, former address and former
fiscal year, if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; width: 49%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Title
of each class</span></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 20%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
Symbol(s)</span></td>
<td style="width: 1%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 29%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of each exchange on which<br /> registered</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember_zXB1FzL4trQ3"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember" name="dei:Security12bTitle">Units,
each consisting of one Class A ordinary share and one-half of one redeemable warrant</ix:nonNumeric></span></span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember_zxYrneM1kN46"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember" name="dei:TradingSymbol">CPAQU</ix:nonNumeric></span></span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_909_edei--SecurityExchangeName_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember_zEgSbs0D0ufg"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
Stock Market LLC</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--ClassOrdinarySharesParValue0.0001PerShareMember_zbu19CsvXcQa"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_ClassOrdinarySharesParValue0.0001PerShareMember" name="dei:Security12bTitle">Class
A ordinary shares, par value $0.0001 per share</ix:nonNumeric></span></span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--ClassOrdinarySharesParValue0.0001PerShareMember_zr3eVXElFxY2"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_ClassOrdinarySharesParValue0.0001PerShareMember" name="dei:TradingSymbol">CPAQ</ix:nonNumeric></span></span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_90E_edei--SecurityExchangeName_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--ClassOrdinarySharesParValue0.0001PerShareMember_zBobnft3FBr7"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_ClassOrdinarySharesParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
Stock Market LLC</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member_z68HV5RVYyXg"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RedeemableWarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member" name="dei:Security12bTitle">Redeemable
warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50</ix:nonNumeric></span></span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member_zrDeXXWeXZA9"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RedeemableWarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member" name="dei:TradingSymbol">CPAQW</ix:nonNumeric></span></span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_90D_edei--SecurityExchangeName_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member_zkPs9NUS7qB6"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RedeemableWarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
Stock Market LLC</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9;&#9;<span id="xdx_907_edei--EntityCurrentReportingStatus_c20220101__20220331_zXn5aXg42G6f"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;</span><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span><span style="font-family: Times New Roman, Times, Serif">&#160;No
</span><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). <span id="xdx_908_edei--EntityInteractiveDataCurrent_c20220101__20220331_z8ji2lXkUWhi"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;</span><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span><span style="font-family: Times New Roman, Times, Serif">&#160;No&#160;</span><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 21%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated
filer</span></td>
<td style="width: 10%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
<td style="width: 21%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 27%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td>
<td style="width: 21%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20220101__20220331_zrFuZrTd8vr6"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntitySmallBusiness_c20220101__20220331_zjbntZPWdtw8"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
<td colspan="2" style="padding-right: 1.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20220101__20220331_zfcqqPbXNskg"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_901_edei--EntityExTransitionPeriod_c20220101__20220331_zR7Ssga46jL8"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <span id="xdx_90E_edei--EntityShellCompany_c20220101__20220331_zsWKkPZ4UlQi"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:EntityShellCompany">Yes</ix:nonNumeric></span>&#160;</span><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>
<span style="font-family: Times New Roman, Times, Serif">No </span><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 13, 2022, there were <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20220513__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zA8pfmyNG8o2" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-05-13_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,102,718</ix:nonFraction></span> Class
A ordinary shares, $0.0001 par value and <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20220513__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zq283zkWJDH4" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-05-13_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,156,250</ix:nonFraction></span> Class B ordinary shares, $0.0001 par value, issued and outstanding.<span style="line-height: 107%"><sup></sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>COUNTER PRESS ACQUISITION CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 90%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 1%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 9%; padding-right: 0.8pt; text-align: center; line-height: 107%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page<span style="line-height: 107%"><sup></sup></span></b></span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I. FINANCIAL INFORMATION</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>1</td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-left: 9pt"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Financial Statements</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;1</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 18pt"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Unaudited </span>Condensed Balance Sheets as of March 31, 2022 <span style="text-decoration: underline">and December 31, 2021</span></span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-left: 18pt"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Unaudited </span>Condensed Statement of Operations for the three months ended March 31, 2022</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-left: 18pt"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Unaudited </span>Condensed Statement of Changes in Shareholders&#8217; Deficit for the three months ended March 31, 2022</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 18pt"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Unaudited </span>Condensed Statement of Cash Flows for the three months ended March 31, 2022</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-left: 18pt"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Unaudited Condensed Financial Statements</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 9pt"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-left: 9pt"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 9pt"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Controls and Procedures</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II. OTHER INFORMATION</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right; padding-right: 0.8pt">17</td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 9pt"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Legal <span style="text-decoration: underline">Proceedings</span></span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 9pt"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A. Risk Factors</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-left: 9pt"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 9pt"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Defaults <span style="text-decoration: underline">Upon Senior Securities</span></span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 9pt"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Mine <span style="text-decoration: underline">Safety Disclosures</span></span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 9pt"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5. Other <span style="text-decoration: underline">Information</span></span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-left: 9pt"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6. Exhibits</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III. SIGNATURES</span></a></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I&#8212;FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span>Item 1. Financial Statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_003"></span>COUNTER PRESS ACQUISITION CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONDENSED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_zqVx93BWAA64" summary="xdx: Statement - CONDENSED BALANCE SHEETS (unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_492_20220331_zoUNbGmaQmba" style="font-weight: bold; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_49C_20211231_zBPLD5FaBXp3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, &#160; 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&#160;31,<br /> 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">(unaudited)</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zd4hCb9GlAu6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_zp4t0ZqxkHab" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Cash_i02I_maCzMX7_zvKP6EF2RvA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; width: 56%; text-indent: -10pt">Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,882</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0056">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_i02I_maCzMX7_zRoPsW5amfnf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">452,407</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0059">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DueFromRelatedPartiesCurrent_i02I_maCzMX7_zGQompwbulIj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Due from related party</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0062">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_i02TI_mtCzMX7_maCz5Ml_zwqCkCkxLehk" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Total Current Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,105,789</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0065">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredOfferingCosts_i01I_maCz5Ml_zFPV8P8QOhdi" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Deferred offering costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0067">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsHeldInTrustNoncurrent_i01I_maCz5Ml_zIxMNm5kPeL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Investment held in Trust Account</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,550,251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0071">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_iTI_mtCz5Ml_zxUqCLqostTc" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,656,040</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zlsPS1TtTtMi" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Liabilities, Class A Ordinary shares Subject to Possible Redemption, and Shareholders&#8217; (Deficit) Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_zM3Kie9sxPYe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AccruedOfferingCostsAndExpenses_i01I_maCzSaY_zYdJR1bV54U3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued offering costs and expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CPEQU:AccruedOfferingCostsAndExpenses" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,678</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CPEQU:AccruedOfferingCostsAndExpenses" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,102</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DueToRelatedPartiesCurrent_i01I_maCzSaY_z0KxiCscvoSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Promissory note - related party</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,879</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrent_i01TI_mtCzSaY_maCznhN_zsXnpjYlTL2l" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Current Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,678</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,981</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredUnderwritersDiscount_i01I_pp0p0_maCznhN_zZWtbW2c51H3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred underwriters&#8217; discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CPEQU:DeferredUnderwritersDiscount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,018,750</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_i01TI_mtCznhN_maCzzl2_zDPrfkRRuVS1" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,047,428</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,981</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommitmentsAndContingencies_i01I_zSQefSjZKmea" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Commitments and Contingencies (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockRedemptionAmount_i01I_maCzzl2_zXvUeGC12Quk" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Class A ordinary shares subject to possible redemption, <span id="xdx_90D_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20220331_zZGp4K6T2un3" title="Temporary Equity, Shares Authorized"><span id="xdx_90C_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20211231_zudWTYghN2Ej" title="Temporary Equity, Shares Authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,625,000</ix:nonFraction></ix:nonFraction></span></span> and no shares at redemption value of $<span id="xdx_903_eus-gaap--TemporaryEquityRedemptionPricePerShare_iI_c20220331_znGlSXOZQaye" title="Temporary Equity, Redemption Price Per Share"><span id="xdx_90B_eus-gaap--TemporaryEquityRedemptionPricePerShare_iI_c20211231_zqD7Ld1g2w87" title="Temporary Equity, Redemption Price Per Share"><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.15</ix:nonFraction></ix:nonFraction></span></span> per share as of March 31, 2022 and December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockRedemptionAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,543,750</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0101">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquityAbstract_iB_zr9IapZL5KIj" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shareholders&#8217; (Deficit) Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PreferredStockValue_iI_maSEzEDu_zQ6UBWeU03P7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Preferred stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220331_pdd" title="Preferred Stock, Par Value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zL8VdyjGZ8V1" title="Preferred Stock, Par Value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20220331_pdd" title="Preferred Stock, Shares Authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zn4UyVJ0eSsl" title="Preferred Stock, Shares Authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_dn_c20220331_zVi80bpuqmTf" title="Preferred Stock, Shares Issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20220331_zwfn8WMVOcQf" title="Preferred Stock, Shares Outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_dn_c20211231_z5TwVgKCpfc" title="Preferred Stock, Shares Issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_zgqoLnYEJSek" title="Preferred Stock, Shares Outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0114">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0115">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Class A ordinary shares, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pdd" title="Ordinary shares, par value"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zCimupz6zdrf" title="Ordinary shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pdd" title="Ordinary shares,, Shares Authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zBTwh2A4MxK" title="Ordinary shares,, Shares Authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_905_eus-gaap--CommonStockSharesIssued_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pdd" title="Ordinary shares, Shares Issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pdd" title="Ordinary shares, Shares Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">510,625</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zSedXmomeh2c" title="Ordinary shares, Shares Issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zkO8GOyc6SFd" title="Ordinary shares, Shares Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31_custom_ClassAOrdinarySharesMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_ClassAOrdinarySharesMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding (excluding 8,625,000 shares subject to possible redemption) as of March 31, 2022 and December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--CommonStockValue_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_pp0p0" title="Ordinary shares, value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--CommonStockValue_iI_pp0p0_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zZB4GZ3XJvi1" title="Ordinary shares, value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Class B ordinary shares, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pdd" title="Ordinary shares, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zIyYZj4ASlN3" title="Ordinary shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pdd" title="Ordinary shares,, Shares Authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zGXf5gqse4B6" title="Ordinary shares,, Shares Authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_902_eus-gaap--CommonStockSharesIssued_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pdd" title="Ordinary shares, Shares Issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pdd" title="Ordinary shares, Shares Outstanding"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zDqAsgTNLwv9" title="Ordinary shares, Shares Issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zY9ulxi44xmj" title="Ordinary shares, Shares Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,156,250</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span>&#160;shares issued and outstanding as of March 31, 2022 and December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--CommonStockValue_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_pp0p0" title="Ordinary shares, value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">216</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CommonStockValue_iI_pp0p0_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z4XXYKuhTPb4" title="Ordinary shares, value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">216</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_iI_maSEzEDu_zHu6tiEz5iwf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,784</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maSEzEDu_zVocVBlVop5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,405</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,917</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_iTI_pp0p0_mtSEzEDu_maCzzl2_ztl2XVoAW6P9" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total shareholders&#8217; (deficit) equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,935,138</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,083</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzzl2_zTENVIt5hycl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities, Class A Ordinary shares Subject to Possible Redemption, and Shareholders&#8217; (Deficit) Equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,656,040</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,064</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of the
condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_004"></span>COUNTER PRESS ACQUISITION CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;<b>UNAUDITED CONDENSED STATEMENT OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_113_zxDzAvJjy2Dl" summary="xdx: Statement -  UNAUDITED CONDENSED STATEMENT OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_497_20220101__20220331_z7PHrXu3dyV" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Three Months Ended<br /> March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpenses_msCzHEu_zAebi9LuATMe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Operating and formation costs</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">435,263</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_mtCzHEu_maNILz7fG_zg586OASX0ld" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-weight: bold; text-align: left; text-indent: -10pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">435,263</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zDgVRdJIaOzi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_i01_maNIEzoky_zVELlybNhRb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Interest earned on marketable securities held in Trust Account</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzoky_maNILz7fG_zWxB6cIaAnE9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total other income&#9;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILz7fG_zKIAvsQe5VOf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">428,762</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WeightedAverageSharesOutstandingClassOrdinarySharesSubjectToRedemption_zkgdiL7QFMJk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Weighted average shares outstanding, Class A ordinary shares subject to redemption</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CPEQU:WeightedAverageSharesOutstandingClassOrdinarySharesSubjectToRedemption" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,600,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--BasicAndDilutedNetIncomePerShareClassOrdinarySharesSubjectToRedemption_zdJLqmfjJzn1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Basic and diluted net income per share, Class A ordinary shares subject to redemption</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CPEQU:BasicAndDilutedNetIncomePerShareClassOrdinarySharesSubjectToRedemption" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.55</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WeightedAverageSharesOutstandingOrdinaryShares_zhaD3wR58vHb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Weighted average shares outstanding, ordinary shares</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CPEQU:WeightedAverageSharesOutstandingOrdinaryShares" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,428,583</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--BasicAndDilutedNetLossPerShareOrdinaryShares_ziycSBEqarxi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Basic and diluted net loss per share, ordinary shares</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="CPEQU:BasicAndDilutedNetLossPerShareOrdinaryShares" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of the
unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>COUNTER PRESS ACQUISITION CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_005"></span>UNAUDITED CONDENSED STATEMENT OF CHANGES IN SHAREHOLDERS&#8217;
DEFICIT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_znUz4hrGgY5i" summary="xdx: Statement - UNAUDITED CONDENSED STATEMENT OF CHANGES IN SHAREHOLDER&apos;S DEFICIT" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_custom--ClassAOrdinarySharesMember_z64aogoqCcSi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_custom--ClassBOrdinarySharesMember_z57WLwB4uCb9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zjgS4yBxVDcl" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zxlHHELTJm82" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BA_zywI96o2Z0si" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class A Ordinary Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Class B Ordinary Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Additional &#160; Paid-in</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Total &#160; Shareholders&#8217;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity (Deficit)</td></tr>
  <tr id="xdx_430_c20220101__20220331_eus-gaap--StockholdersEquity_iS_z2e5uXaVkXb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 37%; font-weight: bold; text-indent: -10pt">Balance &#8212; January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_zJEnAYxRJP0c" title="Balance at beginning, shares" style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0211">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--ClassBOrdinarySharesMember_zkMNlH9WulN8" title="Balance at beginning, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_ClassBOrdinarySharesMember617413109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,156,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_ClassBOrdinarySharesMember617413109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,784</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,917</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,083</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SaleOf471875PrivateUnitsNetOfAllocatedOfferingCosts_zm6S3G9C3epj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Sale of 471,875 Private Units net of allocated offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SaleOf471875PrivateUnitsNetOfAllocatedOfferingCostsShares_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_zNA22RRjyDB3" title="Sale of 471,875 Private Units net of allocated offering costs , shares" style="text-align: right"><ix:nonFraction name="CPEQU:SaleOf471875PrivateUnitsNetOfAllocatedOfferingCostsShares" contextRef="From2022-01-012022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:SaleOf471875PrivateUnitsNetOfAllocatedOfferingCosts" contextRef="From2022-01-012022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0216">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:SaleOf471875PrivateUnitsNetOfAllocatedOfferingCosts" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,718,703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:SaleOf471875PrivateUnitsNetOfAllocatedOfferingCosts" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,718,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FairValueOf4312500publicWarrantsNetOfAllocatedOfferingCosts_zI1yNUzEtyn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fair value of&#160;4,312,500&#160;Public Warrants net of allocated offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0223">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0224">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:FairValueOf4312500publicWarrantsNetOfAllocatedOfferingCosts" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,911,303</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:FairValueOf4312500publicWarrantsNetOfAllocatedOfferingCosts" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,911,303</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IssuanceOf38750UnderwriterFounderShares_zBheJ8Kd7SCf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Issuance of 38,750 Underwriter Founder Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--IssuanceOf38750UnderwriterFounderSharesShares_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_z8UmPBvWpHB3" title="Issuance of 38,750 Underwriter Founder Shares ,shares" style="text-align: right"><ix:nonFraction name="CPEQU:IssuanceOf38750UnderwriterFounderSharesShares" contextRef="From2022-01-012022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:IssuanceOf38750UnderwriterFounderShares" contextRef="From2022-01-012022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:IssuanceOf38750UnderwriterFounderShares" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">446</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:IssuanceOf38750UnderwriterFounderShares" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccretionOfCarryingValueToRedemptionValue_z40DqBQyKFZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Accretion of carrying value to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CPEQU:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,655,236</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CPEQU:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,499,726</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CPEQU:AccretionOfCarryingValueToRedemptionValue" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,154,962</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">428,762</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">428,762</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20220101__20220331_eus-gaap--StockholdersEquity_iE_z89qssii6gV7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Balance &#8211; March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_zukHCaHcY3Xl" title="Balance at ending, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember617413125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">510,625</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember617413125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--ClassBOrdinarySharesMember_zwEA5YFKlDEf" title="Balance at ending, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember617413125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,156,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember617413125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,405</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,935,138</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of the
unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>COUNTER PRESS ACQUISITION CORPORATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_006"></span>UNAUDITED CONDENSED STATEMENT OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_112_zzax3VBSRYK6" summary="xdx: Statement - UNAUDITED CONDENSED STATEMENT OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_490_20220101_20220331" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Three Months Ended<br /> March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zD8Mpos3yea" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows from Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i01_maCzp1J_zBIrCRznfpt1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">428,762</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustments to reconcile net income (loss) to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestAndFeeIncomeNonmortgageLoansAndLeasesHeldForSale_i02N_di_msCzp1J_z2XBbxji42Uj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Interest earned on marketable securities held in Trust Account</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestAndFeeIncomeNonmortgageLoansAndLeasesHeldForSale" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,501</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_i02B_zF3eAuEJssTd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_di_msCzp1J_zzwmkUxtQ0v2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">452,407</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maCzp1J_zwyIsWILgc7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,424</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInDueFromRelatedParties_i03N_di_msCzp1J_zkBEMBBjTKP8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-align: left; text-indent: -10pt">Due from related party</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzp1J_maCzWS6_zi1QOjsvylM2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 40pt; font-weight: bold; text-align: left; text-indent: -10pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">904,594</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zad692xZLxje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows from Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsToInvestInDecommissioningFund_i01N_di_msCzioH_zQIXityJMSQc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Investment held in Trust Account</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToInvestInDecommissioningFund" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,543,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzioH_maCzWS6_zTfPtQqs6zr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 40pt; font-weight: bold; text-align: left; text-indent: -10pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">87,543,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_i01B_zUAYK6rsIHmi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows from Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i02_maCzGwq_zdRxjPytngRj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Proceeds from sale of Units, net of underwriting discounts paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,525,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i02_maCzGwq_zgsM6NZtuL3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Proceeds from sale of Private Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,718,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_i02_maCzGwq_z9j86KvvanZ8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Issuance of Underwriter Founder Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromRelatedPartyDebt_i02_maCzGwq_zdfsThdx0kZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Proceeds from issuance of promissory note to related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RepaymentsOfRelatedPartyDebt_i02N_pp0p0_di_msCzGwq_zSZ4V2jeKvha" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Repayment of promissory note&#8201;&#8211;&#8201;related party</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">175,609</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i02T_mtCzGwq_maCzWS6_zj8WSMV6isWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 40pt; font-weight: bold; text-align: left; text-indent: -10pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,094,226</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzWS6_zpuYw4Yopddc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Change in Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">645,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_z2UsimrR2jZ2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cash &#8211; Beginning of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0_zXvV3XTDri13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Cash &#8211; End of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">645,882</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Non-Cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredUnderwritingCommissionsChargedToAdditionalPaidInCapital_i01_zoWLXSbdr4C5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred underwriting commissions charged to additional paid in capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CPEQU:DeferredUnderwritingCommissionsChargedToAdditionalPaidInCapital" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,018,750</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredOfferingCostsPaidBySponsorUnderPromissoryNote_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred offering costs paid by the promissory note</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CPEQU:DeferredOfferingCostsPaidBySponsorUnderPromissoryNote" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">97,095</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--InitialValueOfOrdinarySharesSubjectToPossibleRedemption_i01_zJYf7a5ODaoe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Initial value of ordinary shares subject to possible redemption</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CPEQU:InitialValueOfOrdinarySharesSubjectToPossibleRedemption" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,543,750</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--TemporaryEquityAccretionToRedemptionValue_i01_zFQy6YN1MnN2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Accretion of carrying value to redemption value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,154,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of the
unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_007"></span>NOTES TO COUNTER PRESS ACQUISITION CORPORATION</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>MARCH 31, 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_80C_eus-gaap--NatureOfOperations_zgIcwdrcTIXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1. <span id="xdx_82E_zh8X3Jyv8m9b">ORGANIZATION, BUSINESS OPERATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Counter Press Acquisition Corporation (the &#8220;Company&#8221;)
is a blank check company incorporated as a Cayman Islands exempted company on May 19, 2021 whose purpose is to enter into a merger, share
exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar Business Combination with one or more businesses
or entities (the &#8220;Business Combination&#8221;). The Company has not selected any specific Business Combination target and it has
not (nor has anyone on its behalf), initiated any substantive discussions, directly or indirectly, with any Business Combination target.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2022, the Company had not commenced
any operations. All activity for the period from May 19, 2021 (inception) through March 31, 2022 relates to the Company&#8217;s formation,
initial public offering (&#8220;Initial Public Offering&#8221; or &#8220;IPO&#8221;), which is described below, and subsequent to the
Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues
until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the
form of interest income on cash and cash equivalents from the proceeds derived from the IPO. The Company has selected December 31 as its
fiscal year end.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The registration statement for the Company&#8217;s
IPO was declared effective on February 8, 2022 (the &#8220;Effective Date&#8221;). The Company&#8217;s sponsor is Counter Press Sponsor
LLC, a Cayman Islands limited liability company (the &#8220;Sponsor&#8221;). On February 11, 2022, the Company consummated the IPO of
<span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220201__20220211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zlDfMC9OT6z1" title="Sale of units"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-02-012022-02-11_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,625,000</ix:nonFraction></span> units (including the full exercise of the underwriter&#8217;s overallotment option of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220201__20220211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zdIBLP78aFDg" title="Sale of units"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-02-012022-02-11_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,125,000</ix:nonFraction></span> units) at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20220211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zPrmhlyTgmy2" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-02-11_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit (the
&#8220;Units&#8221;), generating gross proceeds of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20220201__20220211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3w4W5aa12mg" title="Gross proceeds"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-02-012022-02-11_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">86,250,000</ix:nonFraction></span>, which is discussed in Note 3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simultaneously with the closing of the IPO and the
issuance and sale of the Units, the Company consummated in the aggregate, the sale of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zDcQ5ziqCjNi" title="Sale of units"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-01-012022-03-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,875</ix:nonFraction></span> units (the &#8220;Private Units&#8221;)
at a price of $10.00 per Private Unit, to the Sponsor, EarlyBirdCapital, Inc. (&#8220;EBC&#8221;) and BTIG, LLC (&#8220;BTIG&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of February 11, 2022, transaction costs amounted
to $<span id="xdx_90A_ecustom--TransactionCosts_pp0p0_c20220201__20220211_z3aKUOC2YFWi" title="Transaction costs"><ix:nonFraction name="CPEQU:TransactionCosts" contextRef="From2022-02-012022-02-11" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,949,909</ix:nonFraction></span> consisting of $<span id="xdx_906_eus-gaap--UnderwritingIncomeLoss_pp0p0_c20220201__20220211_zD5D6jZh6Xtk" title="Underwriting commissions"><ix:nonFraction name="us-gaap:UnderwritingIncomeLoss" contextRef="From2022-02-012022-02-11" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,725,000</ix:nonFraction></span> of underwriting commissions, $<span id="xdx_90D_ecustom--DeferredUnderwritingCommissions_pp0p0_c20220201__20220211_zW0kqibPbgC7" title="Deferred underwriting commissions"><ix:nonFraction name="CPEQU:DeferredUnderwritingCommissions" contextRef="From2022-02-012022-02-11" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,018,750</ix:nonFraction></span> of deferred underwriting commissions and $<span id="xdx_906_eus-gaap--OtherOwnershipInterestsOfferingCosts_iI_pp0p0_c20220211_zpiCvXqwAaSa" title="Other offering costs"><ix:nonFraction name="us-gaap:OtherOwnershipInterestsOfferingCosts" contextRef="AsOf2022-02-11" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">206,159</ix:nonFraction></span> of other
cash offering costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">The Company must complete one or more initial
Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding taxes
payable on the interest earned on the Trust Account) at the time of signing a definitive agreement in connection with the Business Combination.
The Company will complete the initial Business Combination only if the post-transaction company in which its public shareholders own shares
will own or acquire 50% or more of the issued and outstanding voting securities of the target or is otherwise not required to register
as an investment company under the Investment Company Act (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company
will be able to complete a Business Combination successfully.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">Following the closing of the IPO on February
11, 2022, $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210201__20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zlkke92PH5H" title="Proceeds from initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-02-012021-02-11_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,543,750</ix:nonFraction></span> ($10.15 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Units was
placed in a Trust Account and, will be held in a U.S.-based trust account (&#8220;Trust Account&#8221;) and will be invested only in U.S.
government treasury bills with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under
the Investment Company Act which invest only in direct U.S. government treasury obligations. Based on current interest rates, the Company
estimates that the interest earned on the Trust Account will be approximately $17,509 per year, assuming no exercise of the underwriters&#8217;
overallotment option and an interest rate of 0.02% per year, following the investment of such funds in specified U.S. government treasury
bills or in specified money market funds. Except with respect to the exceptions described below, the proceeds from the IPO and the sale
of the private units will not be released from the Trust Account until the earliest of: (i) the completion of the initial Business Combination;
(ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Company&#8217;s amended
and restated memorandum and articles of association to (A) modify the substance or timing of the Company&#8217;s obligation to allow redemption
in connection with the initial Business Combination or to redeem the public shares if the Company does not complete the initial Business
Combination within Combination Period or (B) with respect to any other provision relating to shareholders&#8217; rights or pre-Business
Combination activity; and (iii) the redemption of all of the public shares if the Company is unable to complete the initial Business Combination
within Combination Period (as defined below), subject to applicable law. The net proceeds deposited in the Trust Account could become
subject to the claims of the Company&#8217;s creditors, if any, which could have priority over the claims of its public shareholders.
Therefore, there is no guarantee that investors will receive $10.15 per share upon redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">The Company will provide its shareholders
with the opportunity to sell their shares to the Company by means of a tender offer (and thereby avoid the need for a shareholder vote)
for an amount equal to their pro rata share of the aggregate amount then on deposit in the Trust Account (net of amounts required to pay
its income and franchise taxes), in each case subject to the limitations described herein. The decision as to whether the Company will
seek shareholder approval of its proposed Business Combination or allow shareholders to sell their shares to the Company in a tender offer
will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction
and whether the terms of the transaction would otherwise require the Company to seek shareholder approval. If the Company determine to
engage in a tender offer, the Company will file tender offer documents which will contain substantially the same financial and other information
about the initial Business Combination as is required under the SEC&#8217;s proxy rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">The Company will provide its public shareholders
with the opportunity to redeem their Class A ordinary shares upon approval of any such amendment at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable)
divided by the number of then issued and outstanding public shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">The ordinary shares subject to redemption
will be recorded at a redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Financial
Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing
Liabilities from Equity.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 7; Value: 1 -->
    <div id="xdx_23D_zxFs8ghHXjCk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23D_z9t1kRJ0uuHe" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div id="xdx_239_zQc1pYJiuSl9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zsOxEaceb511" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zaaHhceQ1Vra" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO COUNTER PRESS ACQUISITION CORPORATION</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zXQXLErcDa95" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zKLHAZyc4oBf" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>MARCH 31, 2022</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zEuJU4e1g8h7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">The Company will have 12 months from the
closing of the IPO to complete the initial Business Combination (the &#8220;Combination Period&#8221;), the Company may, at the Sponsor&#8217;s
option, extend the period of time to consummate a Business Combination up to two times without shareholder approval, each for an additional
three months (for a total of up to 18 months to complete a Business Combination) (each such three-month period, an &#8220;Extension Period&#8221;)
or during any Extension Period. If the Company is unable to complete the initial Business Combination within the Combination Period, the
Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than
ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit
in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $100,000 of interest to pay dissolution
expenses) divided by the number of then issued and outstanding public shares, which redemption will completely extinguish public shareholders&#8217;
rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of its remaining shareholders and its board of directors,
liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors
and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s
warrants, which will expire worthless if the Company fails to complete the initial Business Combination within Combination Period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">The Sponsor, officers and directors will
enter into a letter agreement with the Company, pursuant to which they will agree (A) to waive their redemption rights with respect to
their shares in connection with the completion of the initial Business Combination and (B) to waive their rights to liquidating distributions
from the Trust Account with respect to their founders and private shares if the Company fails to complete the initial Business Combination
within Combination Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any public
shares they hold if the Company fails to complete the initial Business Combination within the prescribed time frame), as described herein
and in the Company&#8217;s amended and restated memorandum and articles of association.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">The Sponsor has agreed that it will be liable
to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent auditors) for services rendered
or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement,
reduce the amount of funds in the Trust Account to below (i) $10.15 per public share or (ii) such lesser amount per public share held
in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each
case net of the interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party
who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s
indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. Moreover, in the
event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of
any liability for such third party claims. Because the Company is a blank check company, rather than an operating company, and the Company&#8217;s
operations will be limited to searching for prospective target businesses to acquire, the only third parties the Company currently expect
to engage would be vendors such as lawyers, investment bankers, computer or information and technical services providers or prospective
target businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">In connection with the Company&#8217;s assessment
of going concern considerations in accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, &#8220;Disclosures of Uncertainties
about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; management believes that the funds which the Company has available
following the completion of the Initial Public Offering will enable it to sustain operations for a period of at least one-year from the
issuance date of this financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">The Company&#8217;s liquidity needs up to
the closing of the IPO on February 11, 2022 had been satisfied through a payment from the Sponsor of $<span id="xdx_90B_ecustom--ProceedFromSponsors_c20220331_pp0p0" title="Proceed from sponsors"><ix:nonFraction name="CPEQU:ProceedFromSponsors" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span> (see Note 5) for the Founder
Shares to cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of $<span id="xdx_90D_eus-gaap--LoansPayable_c20220331__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredPromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_pp0p0" title="Loan"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-03-31_custom_UnsecuredPromissoryNoteMember_custom_SponsorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span> (see Note 5). The
promissory note was fully repaid as of the closing of the IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">In order to finance transaction costs in
connection with a Business Combination, the Company&#8217;s Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s officers
and directors committed to provide the Company with Working Capital Loans up to $<span id="xdx_90A_ecustom--WorkingCapitalLoans_c20220331_pp0p0" title="Working Capital Loans"><ix:nonFraction name="CPEQU:WorkingCapitalLoans" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span>, as defined later (see Note 5). To date, there
were no amounts outstanding under any Working Capital Loans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">Based on the foregoing, management believes
that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation
of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing
accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective
target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating
and consummating the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify"><b>Risks and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">Management is currently evaluating the impact
of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s
financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of
the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of
this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-indent: 20pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="CPEQU:SignificantAccountingPoliciesTextBloc"><p id="xdx_800_ecustom--SignificantAccountingPoliciesTextBloc_zMqi6DeGfIPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2. <span id="xdx_828_zNqUCQgHI9el">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z4nFEo4I6JTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z8ahKjYrXo4g">Basis of Presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for
interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain
information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or
omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information
and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management,
the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are
necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div id="xdx_239_zQtvP2W01211" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_236_zUuszmYtvyK3" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zf8uuWIY6hq8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_z7uAqXBoQM5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zQEvkIdb7bgl" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO COUNTER PRESS ACQUISITION CORPORATION</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zKAoI5REmRK8" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zHnjtAu2zbIh" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>MARCH 31, 2022</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zFsSw2e2JpMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed financial
statements should be read in conjunction with the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on February 17, 2022.
The interim results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year
ending December 31, 2022 or for any future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="CPEQU:EmergingGrowthCompanyStatusPolicyTextBlock"><p id="xdx_848_ecustom--EmergingGrowthCompanyStatusPolicyTextBlock_zEP5opj19G49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zZDwccpz6mh6">Emerging Growth Company</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is an &#8220;emerging growth company,&#8221;
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;),
and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and
proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84A_eus-gaap--UseOfEstimates_zDOi1EiUjPI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zxvSnpvoU473">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of condensed financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during
the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z3KaWGkrPlNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zAzTklWaGvy7">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all short-term investments with
an original maturity of three months or less when purchased to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_84B_eus-gaap--InvestmentPolicyTextBlock_zDoL65DIHIja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_866_z1vHvZeLkZha">Investment Held in Trust Account</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2022, the Company had $<span id="xdx_904_eus-gaap--AssetsHeldInTrustNoncurrent_c20220331_pp0p0" title="Investment held in Trust Account"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,550,251</ix:nonFraction></span>
in investment held in the Trust Account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zyyiL1lkEvte" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_862_zEj6ojE4nu2c">Concentration of Credit Risk</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the
Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal
Depository Insurance Corporation limit of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20220331_z2mBN5zzX3j8" title="Federal depository insurance corporation coverage"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>. At March 31, 2022, the Company has not experienced losses on this account and management
believes the Company is not exposed to significant risks on such account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="CPEQU:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_84E_ecustom--DeferredOfferingCostsPolicyTextBlock_zuBFvqEUWCla" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zAGDCUIjNr6d">Offering Costs Associated with IPO</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Offering costs consist of underwriting, legal, accounting,
registration and other expenses incurred through the balance sheet date that are directly related to the IPO. As of March 31, 2022, offering
costs amounted to $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_pp0p0_c20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRiNdIPIeKwd" title="Offering cost"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2022-03-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,949,909</ix:nonFraction></span> consisting of $<span id="xdx_90B_ecustom--UnderwritingFees_iI_c20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zJYbkNpKOBzh" title="Underwriting fees"><ix:nonFraction name="CPEQU:UnderwritingFees" contextRef="AsOf2022-03-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,725,000</ix:nonFraction></span> of underwriting fees, $<span id="xdx_904_ecustom--DeferredUnderwritingFees_c20220101__20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNmSIY1v8atk" title="Deferred underwriting fees"><ix:nonFraction name="CPEQU:DeferredUnderwritingFees" contextRef="From2022-01-012022-03-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,018,750</ix:nonFraction></span> of deferred underwriting fees, and $<span id="xdx_903_eus-gaap--OtherOwnershipInterestsOfferingCosts_iI_pp0p0_c20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zGzGSBmOhEbj" title="Other offering costs"><ix:nonFraction name="us-gaap:OtherOwnershipInterestsOfferingCosts" contextRef="AsOf2022-03-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">206,159</ix:nonFraction></span> of
other offering costs. The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A &#8211;
&#8220;Expenses of Offering&#8221;. The Company allocates offering costs between public shares and public warrants&#8239;based on the
estimated fair values of public shares and public warrants at the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="CPEQU:ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock"><p id="xdx_84F_ecustom--ClassAOrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_zlGWwZY6UPwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zzYGH5nx7Yte">Class A Ordinary Shares Subject to Possible
Redemption</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for its ordinary shares subject
to possible redemption in accordance with the guidance in ASC Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary
shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable
ordinary shares (including ordinary shares that feature redemption rights that is either within the control of the holder or subject to
redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At
all other times, ordinary shares is classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares features certain redemption
rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly,
ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders&#8217;
equity section of the Company&#8217;s balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_23B_zvWCrl2tVoE2" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zxnOkAKhKeyj" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_z2kdV1PJ4ry4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zO1BVllt8Xxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_z8kHihvaE3gf" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO COUNTER PRESS ACQUISITION CORPORATION</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zRLIs3aA7Meb" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zs36VkkqWou1" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>MARCH 31, 202</b></p></ix:exclude>


<ix:exclude><p id="xdx_23A_zhKjPSIq1Wla" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2022, the Class A ordinary shares
reflected in the balance sheet is reconciled in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_znNr9CYo0DTl" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span id="xdx_8BC_zzHpHDJ4Zow8" style="display: none">Schedule Of Condensed Balance Sheet</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220101__20220331_zTocyAH0Blf1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_zFuCXt7F83Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; text-indent: -9pt; padding-left: 9pt">Gross Proceeds</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ProceedsAllocatedToPublicWarrants_zhQxBoxzlh9i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Proceeds allocated to public warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CPEQU:ProceedsAllocatedToPublicWarrants" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,027,672</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IssuanceCostsRelatedToClassOrdinaryShares_zouWqbFsj52i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance costs related to Class A ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CPEQU:IssuanceCostsRelatedToClassOrdinaryShares" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,833,540</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Plus:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0p0_zuOFL5Wj3lM2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Accretion of carrying value to redemption value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,154,962</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ContingentlyRedeemableClassOrdinaryShares_pp0p0_z1BIwBJ8Sja2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Contingently redeemable Class A ordinary shares</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CPEQU:ContingentlyRedeemableClassOrdinaryShares" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,543,750</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zTcrRuIJPIM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_z8O6XeJb9Ikf">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Company&#8217;s assets and liabilities,
excluding the warrant liability, which qualify as financial instruments under FASB ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;),
approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DerivativesReportingOfDerivativeActivity"><p id="xdx_844_eus-gaap--DerivativesReportingOfDerivativeActivity_zeqLTjSC9LV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zI64wwc6Cbbg">Derivative Financial Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its financial instruments to
determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815,
&#8220;Derivatives and Hedging&#8221;. The Company&#8217;s derivative instruments are recorded at fair value on the balance sheets with
changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheet
as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months
of the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:StandardProductWarrantyPolicy"><p id="xdx_84C_eus-gaap--StandardProductWarrantyPolicy_zBVUTGAjeqJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zk2ynph8d577">Warrants</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for warrants in accordance with
the guidance contained in FASB ASC 815, &#8220;Derivatives and Hedging&#8221;. Under ASC 815-40 warrants that meet the criteria for equity
treatment are recorded in shareholders&#8217; equity. The warrants are subject to re-evaluation of the proper classification and accounting
treatment at each reporting period. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability
and remeasured each period with changes recorded in the statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zNPksy0DnN15" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_z2LqclMWu2n5">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the asset and liability method
of accounting for income taxes under FASB ASC 740, &#8220;Income Taxes.&#8221; Deferred tax assets and liabilities are recognized for
the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets
and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances
are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC Topic 740 prescribes a recognition threshold and
a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.
The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of March 31, 2022 and December 31, 2021,
there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues
under review that could result in significant payments, accruals or material deviation from its position. The Company&#8217;s management
does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is considered to be an exempted Cayman
Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing
requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zPzbARkOW1tb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zix6oFpg9z76">Net Loss per Ordinary Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary shares is computed by dividing net
income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies the two-class method in
calculating earnings per share. Accretion associated with the redeemable shares of Class A ordinary shares is excluded from earnings per
share as the redemption value approximates fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The calculation of diluted income (loss) per share
does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement
since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase <span id="xdx_90B_ecustom--WarrantPurchase_c20220101__20220331_zOZla3hNeKpi" title="Warrant purchase"><ix:nonFraction name="CPEQU:WarrantPurchase" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,548,438</ix:nonFraction></span>
Class A ordinary shares in the aggregate. As of March 31, 2022, the Company did not have any dilutive securities or other contracts that
could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted
net loss per ordinary shares is the same as basic net loss per ordinary shares for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_23E_zsJLxYs0zeZk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_231_zbNusmaIdCh3" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zk4qUcvoBJbh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zqfL81vCuKw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zpUftmDVfL7c" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO COUNTER PRESS ACQUISITION CORPORATION</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zF9FhKuTWNZ7" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z6uw6BRPztKi" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>MARCH 31, 202</b></p></ix:exclude>


<ix:exclude><p id="xdx_239_zVJWILpZDeZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reflects the calculation of basic
and diluted net income (loss) per ordinary share (in dollars, except per share amounts):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zCxmddgDJdea" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8BA_zXvhB9QzLP8j" style="display: none">Schedule of Earnings Per Share, Basic and Diluted</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_498_20220101__20220331_zhERIkHawFFl" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Three Months Ended &#160; March 31, 2022</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_pp0p0_zj9ma3CN9arj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">428,762</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--TemporaryEquityAccretionToRedemptionValue_iN_pp0p0_di_zjpURgVY2zIf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accretion of temporary equity to redemption value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,154,962</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_pp0p0_z0wMbDTfTtZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss including accretion of temporary equity to redemption value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,583,724</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RedeemableMember_z0ayxXUvN4f" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NonRedeemableMember_zKYi0xReOoKd" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended &#160; March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Redeemable</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Non-redeemable</td></tr>
  <tr id="xdx_404_ecustom--BasicAndDilutedNetLossPerShareAbstract_iB_zWrMa3CP07n2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NumeratorAbstract_iB_zxX4ypnoSgOd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AllocationOfNetLossIncludingAccretionOfTemporaryEquity_z1LsEecZRWrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">Allocation of net loss including accretion of temporary equity</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="CPEQU:AllocationOfNetLossIncludingAccretionOfTemporaryEquity" contextRef="From2022-01-012022-03-31_custom_RedeemableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,617,794</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="CPEQU:AllocationOfNetLossIncludingAccretionOfTemporaryEquity" contextRef="From2022-01-012022-03-31_custom_NonRedeemableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,965,930</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--TemporaryEquityAccretionToRedemptionValue_pp0p0_zd8Qzr0H0jI8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accretion of temporary equity to redemption value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2022-01-012022-03-31_custom_RedeemableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,154,962</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AllocationOfNetIncomeLoss_pp0p0_zijex5dsfUJj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Allocation of net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CPEQU:AllocationOfNetIncomeLoss" contextRef="From2022-01-012022-03-31_custom_RedeemableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,537,168</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="CPEQU:AllocationOfNetIncomeLoss" contextRef="From2022-01-012022-03-31_custom_NonRedeemableMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,965,930</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DenominatorAbstract_iB_zXaChV2G07Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--WeightedaverageSharesOutstanding_zwEfHHq8Bna" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Weighted-average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:WeightedaverageSharesOutstanding" contextRef="From2022-01-012022-03-31_custom_RedeemableMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,600,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CPEQU:WeightedaverageSharesOutstanding" contextRef="From2022-01-012022-03-31_custom_NonRedeemableMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,428,583</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--BasicAndDilutedNetIncomeLossPerShare_zjKYT7UrK5p1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Basic and diluted net income (loss) per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CPEQU:BasicAndDilutedNetIncomeLossPerShare" contextRef="From2022-01-012022-03-31_custom_RedeemableMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="CPEQU:BasicAndDilutedNetIncomeLossPerShare" contextRef="From2022-01-012022-03-31_custom_NonRedeemableMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.22</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>



</ix:nonNumeric></ix:nonNumeric><p id="xdx_8A1_zQOp4myAPlU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="CPEQU:RecentlyAdoptedAccountingStandardsPoliciesTextBlock"><p id="xdx_842_ecustom--RecentlyAdoptedAccountingStandardsPoliciesTextBlock_zUDx7V4FpNd6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zCVhKZBG1Gg4">Recently Adopted Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06, Debt-Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40):
Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which simplifies accounting
for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions
that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation
in certain areas. The Company adopted ASU 2020-06 on May 19, 2021 (inception). Adoption of the ASU did not impact the Company&#8217;s
financial position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zsEUr4EOyT2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zeYWzDUf7txb">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management does not believe that any recently issued,
but not effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="CPEQU:PublicOfferingTextBlock"><p id="xdx_807_ecustom--PublicOfferingTextBlock_z5UnMRQKuDsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3. <span id="xdx_82D_zLauJlcr0vOg">PUBLIC OFFERING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2022, the Company consummated its
IPO of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220201__20220211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zcqJZGgOFjv1" title="Sale of units"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-02-012022-02-11_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,625,000</ix:nonFraction></span> Units (including the full exercise of the underwriter&#8217;s overallotment option of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220201__20220211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zx25t2m4cOLd" title="Sale of units"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-02-012022-02-11_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,125,000</ix:nonFraction></span> units), at a price of
$<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20220211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zzicybpqnGTe" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-02-11_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Unit, generating gross proceeds to the Company of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20220201__20220211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zOqoJTduld6f" title="Proceed from sales of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-02-012022-02-11_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">86,250,000</ix:nonFraction></span>. Each Unit consists of one Class A ordinary share and one-half
of one redeemable warrant (the &#8220;Public Warrants&#8221;). Each whole warrant entitles the holder to purchase one Class A ordinary
share at a price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220211_znFVkq0CS6ha" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-11" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span> per share. Each warrant will become exercisable 30 days after the completion of an initial business combination
and will expire on the fifth anniversary of the Company&#8217;s completion of an Initial Business Combination or earlier upon redemption
or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="CPEQU:PrivatePlacementTextBlock"><p id="xdx_807_ecustom--PrivatePlacementTextBlock_z4nMUNWEJx5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4. <span id="xdx_827_zTvZBiyq400a">PRIVATE PLACEMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simultaneously with the consummation of the IPO and
the issuance and sale of the Units, the Company consummated in the aggregate <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20220331__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_pdd" title="Sale of units"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-01-012022-03-31_custom_PrivatePlacementWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,875</ix:nonFraction></span> units (the &#8220;Private Units&#8221;) at a price
of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_c20220331__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_pdd" title="Sale of units per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-03-31_custom_PrivatePlacementWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit, each comprised of one Class A ordinary share and one-half of a warrant (&#8220;Private Warrant&#8221;). These private
units will be sold at a price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220331_zF3Dz10uUuv7" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit for gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20220101__20220331__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_pp0p0" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2022-01-012022-03-31_custom_PrivatePlacementWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,718,750</ix:nonFraction></span>. The Sponsor purchased <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zCIqAon6hlG7" title="Number of shares purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2022-01-012022-03-31_custom_SponsorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">436,416</ix:nonFraction></span> of the private units
and BTIG and EBC collectively purchased <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20220101__20220331_zqOSrr2j0V49" title="Number of shares purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,459</ix:nonFraction></span> of the private units. Each private unit is comprised of one private share and one-half
of a warrant. A portion of the proceeds from the Private Placement Warrants will be added to the proceeds from the IPO to be held in the
Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the
Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and
the Private Placement Warrants will expire worthless.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_23F_zjNV182TXzd2" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zs06VeiJt497" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_za6Z2XJiMw4j" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zdskIuCbuKel" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zjS9FL55SO91" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO COUNTER PRESS ACQUISITION CORPORATION</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zhzBiMx6SnHb" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zAGvgPfRMyzg" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>MARCH 31, 202</b></p></ix:exclude>


<ix:exclude><p id="xdx_232_z5knYdiM6ftc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each private unit is comprised of one private share
and one-half of a warrant. Each whole private warrant is exercisable to purchase one ordinary share at $11.50.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z2CgISM1RcPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5. <span id="xdx_82F_zwqwV7nasBy">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Founder Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 23, 2021, the Sponsor paid $<span id="xdx_907_ecustom--ExchangeOfSharesValue_c20210601__20210623__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--OwnershipAxis__custom--OtherFounderMember_pp0p0" title="Exchange of shares value"><ix:nonFraction name="CPEQU:ExchangeOfSharesValue" contextRef="From2021-06-012021-06-23_custom_SponsorMember_custom_OtherFounderMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span>, or approximately
$0.012 per share, to cover certain offering costs in consideration for <span id="xdx_90B_ecustom--NumberOfSharesExchange_c20210601__20210623__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember__srt--OwnershipAxis__custom--OtherFounderMember_pdd" title="Number of shares exchange"><ix:nonFraction name="CPEQU:NumberOfSharesExchange" contextRef="From2021-06-012021-06-23_custom_SponsorMember_custom_OtherFounderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,156,250</ix:nonFraction></span> Class B ordinary shares, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20210623_pdd" title="Ordinary shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-23" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> (the &#8220;Founder
Shares&#8221;). Up to <span id="xdx_904_ecustom--SharesSubjectToForfeiture_c20210601__20210623_pdd" title="Shares subject to forfeiture"><ix:nonFraction name="CPEQU:SharesSubjectToForfeiture" contextRef="From2021-06-012021-06-23" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">281,250</ix:nonFraction></span> shares are subject to forfeiture by the Sponsor depending on the extent to which the underwriters&#8217;
over-allotment option is exercised. The underwriter founder shares are not subject to forfeiture if the underwriters&#8217; over-allotment
option is not exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to customary, minor exceptions, the Company&#8217;s
Sponsor, as well as its officers and directors, will agree not to transfer, assign or sell any of their founders shares, and to maintain
their founders shares in escrow, until six months after the date of the consummation of our initial business combination (all founder
shares will also be released from escrow and lock-up, if sooner than the above, on the date on which we consummate a liquidation, merger,
amalgamation, share exchange, reorganization or other similar transaction after our initial business combination that results in all of
our shareholders having the right to exchange their ordinary shares for cash, securities or other property).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to customary, minor exceptions, the holders
of the underwriter founder shares will agree not to transfer, assign or sell any such shares without our prior written consent until the
completion of our initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to customary, minor exceptions, all of the
holders of private shares will agree not to transfer, assign or sell any of their private shares until the completion of our initial business
combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Due from related party</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2022, the Company had $<span id="xdx_909_eus-gaap--DueFromRelatedPartiesCurrent_c20220331_pp0p0" title="Due from related party"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,500</ix:nonFraction></span> of due
from related party, which consisted of $25,000 overpayment to the Sponsor and offset by the accrual of $17,500 of administrative services
fees. As of December 31, 2021, the Company had none of due from related party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Promissory Note-Related Party</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2021, the Sponsor agreed to loan the
Company up to $<span id="xdx_900_eus-gaap--LoansPayable_iI_c20210630_zNKek9iUx6dd" title="Loan"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> to be used for a
portion of the expenses of the IPO. These loans are non-interest bearing, unsecured and are due at the earlier of February 28, 2022,
or the closing of the IPO. The loan was repaid upon the closing of the IPO out of the offering proceeds not held in the Trust
Account. As of March 31, 2022 and December 31, 2021, nil <span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220331__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zry6oJxVJujl" title="Debt" style="display: none"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-03-31_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zXMo5JgBJe5a" title="Debt"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,879</ix:nonFraction></span>
were outstanding under the promissory note, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Working Capital Loans</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to finance transaction costs in connection
with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors
may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes
the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to
the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the
initial Business Combination does not close. The Company may use a portion of the working capital held outside the Trust Account to repay
the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $<span id="xdx_90E_ecustom--WorkingCapitalDeficit_c20220101__20220331_pp0p0" title="Working capital deficit"><ix:nonFraction name="CPEQU:WorkingCapitalDeficit" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span> of
such Working Capital Loans may be convertible into units of the post-Business Combination entity at a price of $<span id="xdx_90F_eus-gaap--SharePrice_c20220331_pdd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per unit at the
option of the lender. The units would be identical to the Private Placement Units. As of March 31, 2022 and December 31, 2021, the Company
had no borrowings under the Working Capital Loans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Office Space, Secretarial and Administrative Services</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Commencing on the Effective Date, the Company will
enter into an administrative services agreement pursuant to which it will pay the Sponsor up to $<span id="xdx_90F_eus-gaap--RelatedPartyCosts_c20220101__20220331__us-gaap--RelatedPartyTransactionAxis__custom--AdministrativeSupportAgreementMember_zIJmguEi2tmc" title="Related Party expenses"><ix:nonFraction name="us-gaap:RelatedPartyCosts" contextRef="From2022-01-012022-03-31_custom_AdministrativeSupportAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> per month for office space, administrative
and support services, for up to the 15-month period, which includes the automatic three-month extension period. Upon completion of the
Business Combination or the Company&#8217;s liquidation, it will cease paying these monthly fees. For the three months ended March 31,
2022, the Company incurred $17,500 in fees for these services , of which such amount offset due from related party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_233_z7PAQTNINEV1" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23D_zxNxmVCAmQQ6" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_z1qMchmlnh07" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zmkzOhMCrWlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zTr7eC96LTvh" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO COUNTER PRESS ACQUISITION CORPORATION</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zlrDjHQeBY82" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zYa9Q2hDtBX6" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>MARCH 31, 202</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zC2lAmxEH57h" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p></ix:exclude>


</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zXXFvvFrjGUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE
6. <span id="xdx_82D_zFBxPfdtDQS1">COMMITMENTS &amp; CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Registration Rights</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of the founders shares, private units
(including private warrants), Underwriter Founder Shares and warrants that may be issued on conversion of Working Capital Loans (and any
ordinary shares issuable upon the exercise of the private warrants or warrants issued upon conversion of the Working Capital Loans and
upon conversion of the founders shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed
prior to or on the effective date of the IPO requiring the Company to register such securities for resale. The holders of these securities
will be entitled to make up to two demands, excluding short form registration demands, that the Company register such securities. In addition,
the holders have certain &#8220;piggyback&#8221; registration rights with respect to registration statements filed subsequent to its completion
of the initial Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under
the Securities Act. However, the registration rights agreement provides that the Company will not permit any registration statement filed
under the Securities Act to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred
in connection with the filing of any such registration statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Underwriters Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company granted the underwriters a 45-day option
from the date of the IPO to purchase up to an additional <span id="xdx_901_ecustom--PaymentOfUnderwritingCommissions_pp0p0_c20220101__20220331__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember_zqbtCehymvX2" title="Payment of underwriting commissions"><ix:nonFraction name="CPEQU:PaymentOfUnderwritingCommissions" contextRef="From2022-01-012022-03-31_custom_UnderwritingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,125,000</ix:nonFraction></span> units to cover over-allotments, if any, at the IPO price less the underwriting
discounts and commissions. On February 11, 2021, the underwriters fully exercised their over-allotment option to purchase an additional
<span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220201__20220211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember_zvu2Y7LKdVib" title="Sale of units"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-02-012022-02-11_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,125,000</ix:nonFraction></span> Units<i>.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The underwriters were entitled to a cash underwriting
discount of two percent (<span id="xdx_907_ecustom--CashUnderwritingDiscountPercent_dp_c20220101__20220331__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember_zHBzqYy1AZV6" title="Cash underwriting discount percent"><ix:nonFraction name="CPEQU:CashUnderwritingDiscountPercent" contextRef="From2022-01-012022-03-31_custom_UnderwritingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>%) of the gross proceeds of the IPO, or $<span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember_zkYDouSnmamb" title="Sale of Stock, Number of Shares Issued in Transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-01-012022-03-31_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,725,000</ix:nonFraction></span>. Additionally, the underwriters will be entitled to a deferred
underwriting discount of <span id="xdx_90A_ecustom--UnderwritingDiscountPercent_dp_c20220101__20220331__us-gaap--TransactionTypeAxis__custom--UnderwritingAgreementMember_zcId3NW6ygQ9" title="Underwriting Discount percentage"><ix:nonFraction name="CPEQU:UnderwritingDiscountPercent" contextRef="From2022-01-012022-03-31_custom_UnderwritingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.5</ix:nonFraction></span>% of the gross proceeds of the IPO upon the completion of the Company&#8217;s initial Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zoyIQUSFE093" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7. <span id="xdx_82F_zBzBNJy9RKk2">SHAREHOLDERS&#8217; DEFICIT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Underwriter Founder Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January, prior to the consummation of the IPO,
the Company issued to BTIG and EBC and its designees an aggregate of <span id="xdx_90C_ecustom--NumberOfFounderShares_c20220101__20220131_pdd" title="Number of founder shares"><ix:nonFraction name="CPEQU:NumberOfFounderShares" contextRef="From2022-01-012022-01-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,750</ix:nonFraction></span> Class A ordinary shares (the &#8220;Underwriter Founder Shares&#8221;)
for generating gross proceeds of $<span id="xdx_90F_ecustom--ProceedsFromFounderShares_c20220101__20220131_pp0p0" title="Proceeds from founder shares"><ix:nonFraction name="CPEQU:ProceedsFromFounderShares" contextRef="From2022-01-012022-01-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">450</ix:nonFraction></span>. The Company accounted for the Underwriter Founder Shares as an expense of the IPO, resulting in
a charge directly to Shareholders Equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the holders of the Underwriter Founder
Shares will agree (i) to waive their conversion rights (or right to participate in any tender offer) with respect to such shares in connection
with the completion of our initial business combination and (ii) to waive their rights to liquidating distributions from the trust account
with respect to such shares if we fail to complete our initial business combination within the completion window.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Underwriter Founder Shares have been deemed compensation
by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the commencement of sales of the public
offering pursuant to Rule 5110(e)(1) of the FINRA Manual. Pursuant to FINRA Rule 5110(e)(1), these securities will not be sold during
the offering, or sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put
or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately
following the commencement of sales of the public offering, except to any underwriter and selected dealer participating in the offering
and their officers or partners, registered persons or affiliates provided that all securities so transferred remain subject to the lockup
restriction above for the remainder of the time period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preference shares-</b>The Company is authorized
to issue <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20220331_zBEwz0hDmuE1" title="Preferred Stock, Shares Authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> preference shares with a par value of $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331_z73ztcfuGKGb" title="Preferred Stock, Par Value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> and with such designations, voting and other rights and preferences as
may be determined from time to time by the Company&#8217;s board of directors. As of March 31, 2022 and December 31, 2021, there were
<span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20220331_zCBp63qlPId4" title="Preferred Stock, Shares Issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220331_zxzg9cGSXD3" title="Preferred Stock, Shares Outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> preference shares issued or outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Class A ordinary shares-</b>The Company is authorized
to issue <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_z52a6Lc7X4fi" title="Ordinary shares,, Shares Authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></span> Class A ordinary shares with a par value of $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zpciIfrTnTpk" title="Ordinary shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. As of March 31, 2022, there were <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zte2KcVi6ehe" title="Ordinary shares, Shares Issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zHVbebs7g7Te" title="Ordinary shares, Shares Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31_custom_ClassAOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">510,625</ix:nonFraction></ix:nonFraction></span></span> shares issued
and outstanding (excluding 8,625,000 shares subject to possible redemption). As of December 31, 2021, there were <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zTVwI9LJnoS7" title="Ordinary shares, Shares Issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_do_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zaSvDyzaqTA8" title="Ordinary shares, Shares Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31_custom_ClassAOrdinarySharesMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_ClassAOrdinarySharesMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> Class A ordinary shares
issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Class B ordinary shares-</b>The Company is authorized
to issue <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zb4GpAnoCBL8" title="Ordinary shares,, Shares Authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> Class B ordinary shares with a par value of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zYKd5hHlbqqg" title="Ordinary shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. Holders are entitled to one vote for each Class B ordinary
share. As of March 31, 2022 and December 31, 2021, there were <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zPd8KLuYTRC6" title="Ordinary shares, Shares Issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_zRNksc7n6Y05" title="Ordinary shares, Shares Outstanding"><span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_znzoDq8QLJ2l" title="Ordinary shares, Shares Issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__custom--ClassBOrdinarySharesMember_z97E2GxpbpZ6" title="Ordinary shares, Shares Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31_custom_ClassBOrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,156,250</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> Class B ordinary shares issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Holders of Class A ordinary shares and holders of
Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#8217;s shareholders except
as required by law. Unless specified in the Companies Act, the Company&#8217;s amended and restated memorandum and articles of association
or applicable stock exchange rules, the affirmative vote of a majority of the Company&#8217;s ordinary shares that are voted is required
to approve any matter voted on by its shareholders. Approval of certain actions will require a special resolution under Cayman Islands
law and pursuant to the Company&#8217;s amended and restated memorandum and articles of association; such actions include amending the
Company&#8217;s amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another
company. Directors are appointed for a term of two years. There is no cumulative voting with respect to the appointment of directors,
with the result that the holders of more than 50% of the Founder Shares purchased prior to the IPO that are voted for the appointment
of directors can appoint all of the directors prior to the initial Business Combination. The Company&#8217;s shareholders are entitled
to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Founder Shares will automatically convert into
Class A ordinary shares on the first business day following the completion of the initial Business Combination on a one-for-one basis,
subject to adjustment as provided herein. In the case that additional Class A ordinary shares, or equity-linked securities convertible
or exercisable for Class A ordinary shares, are issued or deemed issued in excess of the amounts issued in the IPO and related to the
closing of the initial Business Combination, the ratio at which founders shares will convert into Class A ordinary shares will be adjusted
(subject to waiver by holders of a majority of the Class B ordinary shares then in issue) so that the number of Class A ordinary shares
issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of its
ordinary shares issued and outstanding upon the completion of the IPO plus the number of Class A ordinary shares and equity-linked securities
issued or deemed issued in connection with the initial Business Combination (net of redemptions), (excluding the underwriter founder shares
and the private shares).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_23D_zA66aP0yq453" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zflisyWacfPl" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zxglkzcx2k8c" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_z6E4xoGFpyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zkglIQbcWs94" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO COUNTER PRESS ACQUISITION CORPORATION</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zWSyUDV2LpZ7" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zZFX6qeburH5" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>MARCH 31, 202</b></p></ix:exclude>


<ix:exclude><p id="xdx_234_zmsaYpAsKs74" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Public Warrants</b> &#8212; As of March 31, 2022,
there were <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220331_ztZCwbodKBkb" title="Warrants Outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,312,500</ix:nonFraction></span> Public Warrants outstanding. As of December 31, 2021, there were no Public Warrants outstanding. Each whole warrant
entitles the holder to purchase one Class A ordinary share at a price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_c20220331_pdd" title="Share Price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span> per share, subject to adjustment. The warrants will become
exercisable 30 days following the completion of the Business Combination. The warrants will expire at 5:00 p.m., New York City time, five
years after the completion of the Business Combination, or earlier upon redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00B0F0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if (x) the Company issue additional Class
A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination
at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price
to be determined in good faith by its board of directors, and in the case of any such issuance to the Sponsor, initial shareholders or
their affiliates, without taking into account any founders shares held by them prior to such issuance) (which the Company refer to as
the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity
proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial
Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the
20 trading day period starting on the trading day prior to the day on which the Company consummate the initial Business Combination (such
price, the &#8220;Market Value&#8221;) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest
cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the Newly Issued Price and the $18.00 per share redemption trigger
price described below under &#8220;Redemption of warrants&#8221; will be adjusted (to the nearest cent) to be equal to 180% of the greater
of (i) the Market Value or (ii) the Newly Issued Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No warrants will be exercisable for cash unless the
registration statement of which this prospectus forms a part (or a different registration statement covering the Class A ordinary shares
issuable upon exercise of the warrants) is then in effect and this prospectus (or such other prospectus that is part of such other registration
statement) is then current. Notwithstanding the foregoing, if a registration statement covering the Class A ordinary shares issuable upon
exercise of the warrants is not then in effect during the period beginning 60 business days following the consummation of the initial
Business Combination, warrant holders may, during any period when the Company shall have failed to maintain an effective registration
statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933,
as amended, or the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available,
holders will not be able to exercise their warrants on a cashless basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Redemption of warrants. Once the warrants become
exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 18pt; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 18pt; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in whole and not in part;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220331__us-gaap--AwardTypeAxis__custom--WarrantsMember_z7Y1hWeZTCmi" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-03-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per warrant;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon a minimum of 30 days&#8217; prior written notice of redemption (the &#8220;Redemption Period&#8221;)</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if, and only if, the last sale price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share consolidations, share capitalizations, rights issuances, reorganizations, recapitalizations and the like, or as described above under &#8220;Exercise price of warrants&#8221;) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending on the third trading day prior to the date on which the Company send the notice of redemption to the warrant holders; and</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there is a current registration statement in effect with respect to the Class A ordinary shares underlying such warrants.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Private Placement Warrants</b>- At March 31, 2022,
there were <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220331__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_zZ9q7y62VFhi" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-03-31_custom_PrivatePlacementWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">235,938</ix:nonFraction></span> Private Placement Warrants outstanding. As of December 31, 2021, there were <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_do_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantsMember_z6YVWcnCp5Pi" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-12-31_custom_PrivatePlacementWarrantsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> Private Placement Warrants outstanding.
The private warrants are identical to the warrants sold as part of the units in this offering except that, so long as they are held by
our sponsor or its permitted transferees: (1) they (including the ordinary shares issuable upon exercise of these warrants) may not, subject
to certain limited exceptions, be transferred, assigned or sold by our sponsor until 30 days after the completion of our initial business
combination; and (2) they (including the ordinary shares issuable upon exercise of these warrants) are entitled to registration rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock"><p id="xdx_807_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zdUvKVXCVESl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8. <span id="xdx_82C_zCRiHdHI0KS4">FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Company&#8217;s financial assets
and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the
assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement
date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs
(market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market
participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based
on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_23F_zcWaZojsmnee" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_235_zMJTSju8tF6l" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zI0VV54Wb9n" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zKf0Lr0c4QB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_z9wFVA8clCs3" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO COUNTER PRESS ACQUISITION CORPORATION</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_z0JEjSGHj2Fc" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z4DcLDNDlxH9" style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>MARCH 31, 202</b></p></ix:exclude>


<ix:exclude><p id="xdx_239_zUoCa5XL88Oc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p></ix:exclude>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1:</span></td>
<td style="width: 87%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices in
active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for
the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2:</span></td>
<td style="width: 87%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable inputs
other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted
prices for identical assets or liabilities in markets that are not active.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 7%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3:</span></td>
    <td style="width: 87%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #2F5496">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2022, investment held in the Trust Account
were comprised of $<span id="xdx_909_eus-gaap--AssetsHeldInTrustNoncurrent_iI_pp0p0_c20220331_zUbr0VASNZ4l" title="Investment held in Trust Account"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,550,251</ix:nonFraction></span> in money market funds which are invested primarily in U.S. Treasury Securities.&#160;Through March 31, 2022,
the Company withdrew $<span id="xdx_907_eus-gaap--RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_c20220101__20220331_pp0p0" title="Interest earned on marketable securities held in Trust Account"><ix:nonFraction name="us-gaap:RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,501</ix:nonFraction></span> of interest earned on the Trust Account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information about the
Company&#8217;s assets that are measured at fair value on a recurring basis at March 31, 2022 and indicates the fair value hierarchy of
the valuation inputs the Company utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zP1Db879IHc4" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; font-weight: bold; text-align: center; text-indent: -10pt"><span id="xdx_8BA_zDJlaybE6Hn1" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: center; text-indent: -10pt">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsHeldInTrustNoncurrent_c20220331_pp0p0" title="Investment held in Trust Account" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,550,251</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zryN57siKjZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9. <span id="xdx_82D_zqbfvdtUy98f">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review,
the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><p id="xdx_815_zMbbWurkWWb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_008"></span>Item 2. Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">References in this report (the &#8220;Quarterly Report&#8221;)
to &#8220;we,&#8221; &#8220;us&#8221; or the &#8220;Company&#8221; refer to Counter Press Acquisition Corporation, references to our &#8220;management&#8221;
or our &#8220;management team&#8221; refer to our officers and directors, and references to the &#8220;Sponsor&#8221; refer to Counter
Press Sponsor LLC. The following discussion and analysis of the Company&#8217;s financial condition and results of operations should be
read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information
contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Special Note Regarding Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report includes &#8220;forward-looking
statements&#8221; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act that are not historical
facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All
statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; regarding the completion of
the Proposed Business Combination (as defined below), the Company&#8217;s financial position, business strategy and the plans and objectives
of management for future operations, are forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221;
&#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;seek&#8221; and variations and similar words and expressions are intended to identify
such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management&#8217;s
current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ
materially from the events, performance and results discussed in the forward-looking statements, including that the conditions of the
Proposed Business Combination are not satisfied. For information identifying important factors that could cause actual results to differ
materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company&#8217;s final
prospectus for its Initial Public Offering filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). The Company&#8217;s
securities filings can be accessed on the EDGAR section of the SEC&#8217;s website at www.sec.gov. Except as expressly required by applicable
securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result
of new information, future events or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a blank check company incorporated as a Cayman
Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses. We have not selected any specific business combination target and we have
not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target.
We intend to effectuate our initial business combination using cash from the net proceeds of our initial public offering and a portion
of the private placement of the private units, our shares, debt or a combination of cash, shares and debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The issuance of additional ordinary shares in a business
combination:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 18pt">&#160;</td>
<td style="width: 18pt; text-align: left">&#9679;</td><td style="text-align: justify">may significantly dilute the equity interest of investors in our initial public offering,
which dilution would increase if the anti-dilution provisions of the Class B ordinary shares resulted in the issuance of Class A ordinary
shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">may subordinate the rights of holders of Class A ordinary shares if preferred shares are
issued with rights senior to those afforded our Class A ordinary shares;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">could cause a change of control if a substantial number of our ordinary shares are issued,
which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation
or removal of our present officers and directors;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">may have the effect of delaying or preventing a change of control of us by diluting the share
ownership or voting rights of a person seeking to obtain control of us; and</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">may adversely affect prevailing market prices for our Class A ordinary shares and/or warrants.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Similarly, if we issue debt securities or otherwise
incur significant indebtedness, it could result in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 18pt">&#160;</td>
<td style="width: 18pt; text-align: left">&#9679;</td><td style="text-align: justify">default and foreclosure on our assets if our operating revenues after an initial business
combination are insufficient to repay our debt obligations;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">acceleration of our obligations to repay the indebtedness even if we make all principal and
interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without
a waiver or renegotiation of that covenant;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">our immediate payment of all principal and accrued interest, if any, if the debt security
is payable on demand;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">our inability to obtain necessary additional financing if the debt security contains covenants
restricting our ability to obtain such financing while the debt security is issued and outstanding;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">our inability to pay dividends on our ordinary shares;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 18pt">&#160;</td>
<td style="width: 18pt; text-align: left">&#9679;</td><td style="text-align: justify">using a substantial portion of our cash flow to pay principal and interest on our debt, which
will reduce the funds available for dividends on our ordinary shares if declared, expenses, capital expenditures, acquisitions and other
general corporate purposes;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">limitations on our flexibility in planning for and reacting to changes in our business and
in the industry in which we operate;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">increased vulnerability to adverse changes in general economic, industry and competitive
conditions and adverse changes in government regulation; and</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&#160;</td>
<td style="text-align: left">&#9679;</td><td style="text-align: justify">limitations on our ability to borrow additional amounts for expenses, capital expenditures,
acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors
who have less debt.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">Although we raised $86,250,000 of gross
proceeds, in the aggregate, from our initial public offering in February 2022, and additional $4,718,750 of gross proceeds, in the aggregate,
from our private placements consummated concurrently with the closing of our initial public offering, we expect to continue to incur significant
costs in the pursuit of our acquisition plans. We cannot assure you that our plans to raise capital or to complete our initial business
combination will be successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have neither engaged in any operations nor generated
any revenues to date. Our only activities from February 11, 2022 (inception) through March 31, 2022 were organizational activities, those
necessary to prepare for the Initial Public Offering, described below, and identifying a target company for a Business Combination. We
do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income
in the form of interest income on marketable securities held in the Trust Account. We incur expenses as a result of being a public company
(for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31, 2022, we had
a net loss of $428,762, which consists of operating costs of $435,263 and offset by interest income on investment held in the Trust Account
of $6,501.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2022, we consummated the IPO of 8,625,000
Units at $10.00 per Unit, generating gross proceeds of $86,250,000. Simultaneously with the closing of the IPO and the issuance and sale
of the Units, we consummated in the aggregate, the sale of 471,875 Private Units at a price of $10.00 per Private Unit, to the Sponsor,
EBC and BTIG.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the Initial Public Offering, and the sale
of the Private Units, a total of $87,543,750 was placed in the Trust Account. We incurred $4,949,909 in Initial Public Offering related
costs, including $1,725,000 of underwriting commissions, $3,018,750 of deferred underwriting commissions and $206,159 of other cash offering
costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31, 2022, cash used
in operating activities was $904,594. Net loss of $428,762 was affected by interest earned on investment held in the Trust Account of
$6,501, and changes in operating assets and liabilities of $469,331.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#8217;s assessment
of going concern considerations in accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, &#8220;Disclosures of Uncertainties
about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; management believes that the funds which the Company has available
following the completion of the Initial Public Offering will enable it to sustain operations for a period of at least one-year from the
issuance date of this financial statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s liquidity needs up to the closing
of the IPO on February 11, 2022 had been satisfied through a payment from the Sponsor of $25,000 (see Note 5) for the Founder Shares to
cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of $150,000. The promissory note was fully
repaid as of the closing of the IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to finance transaction costs in connection
with a Business Combination, the Company&#8217;s Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s officers and
directors committed to provide the Company with Working Capital Loans up to $1,500,000, as defined later (see Note 5). To date, there
were no amounts outstanding under any Working Capital Loans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no obligations, assets or liabilities, which
would be considered off-balance sheet arrangements as of March 31, 2022. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Contractual obligations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any long-term debt, capital lease obligations,
operating lease obligations or long-term liabilities, other than an agreement to pay the Sponsor up to $10,000 per month for office space,
administrative and support services, for up to the 15-month period, which includes the automatic three-month extension period. We began
incurring these fees on February 8, 2022 and will continue to incur these fees monthly until the earlier of the completion of the Business
Combination and our liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">The underwriters are entitled to a cash
underwriting discount of two percent (2%) of the gross proceeds of the IPO, or $1,725,000. Additionally, the underwriters will be entitled
to a deferred underwriting discount of 3.5% of the gross proceeds of the IPO upon the completion of the Company&#8217;s initial Business
Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of condensed financial statements
and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities
at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from
those estimates. We have identified the following critical accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Class A Ordinary Shares Subject to Possible Redemption</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for our ordinary shares subject to possible
conversion in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities
from Equity.&#8221; Ordinary shares subject to mandatory redemption are classified as a liability instrument and measured at fair value.
Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control
of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary
equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. Our ordinary shares feature certain redemption
rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, ordinary shares
subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#8217; equity section
of our condensed balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Net Loss Per Ordinary Share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We comply with accounting and disclosure requirements
of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary shares is computed by dividing net income (loss)
by the weighted average number of ordinary shares outstanding for the period. We apply the two-class method in calculating earnings per
share. Accretion associated with the redeemable shares of Class A ordinary shares is excluded from earnings per share as the redemption
value approximates fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The calculation of diluted income (loss) per share
does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement
since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 4,548,438
Class A ordinary shares in the aggregate. As of March 31, 2022, we did not have any dilutive securities or other contracts that could,
potentially, be exercised or converted into ordinary shares and then share in our earnings. As a result, diluted net loss per ordinary
shares is the same as basic net loss per ordinary shares for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Recent Accounting Standards</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06, Debt-Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40):
Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which simplifies accounting
for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions
that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation
in certain areas. We adopted ASU 2020-06 on May 19, 2021 (inception). Adoption of the ASU did not impact our financial position, results
of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_009"></span>Item 3. Quantitative and Qualitative Disclosures
About Market Risk.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a smaller reporting company as defined by Rule
12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_010"></span>Item 4. Controls and Procedures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disclosure controls are procedures that are designed
with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Form
10-Q, is recorded, processed, summarized, and reported within the time period specified in the SEC&#8217;s rules and forms. Disclosure
controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including
the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management
evaluated, with the participation of our current chief executive officer and chief financial officer (our &#8220;Certifying Officers&#8221;),
the effectiveness of our disclosure controls and procedures as of March 31, 2022, pursuant to Rule 13a-15(b) or Rule 15d-15(b) under the
Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of March 31, 2022 our disclosure controls and procedures
were effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not expect that our disclosure controls and
procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the
design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered
relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls
and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design
of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can
be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There was no change in our internal control over financial reporting that
occurred during the fiscal quarter ended March 31, 2022 covered by this Quarterly Report on Form 10-Q that has materially affected, or
is reasonably likely to materially affect, our internal control over financial reporting.&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_011"></span>PART II&#8212;OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_012"></span>Item 1. Legal Proceedings.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_014"></span>Item 1A. Risk Factors.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Factors that could cause our actual results to differ
materially from those in this report include the risk factors described in our Annual Report on Form 10-K for the year ended December
31, 2021 filed with the SEC on March 31, 2022. As of the date of this Form 10-Q, there have been no material changes to the risk factors
disclosed in our Annual Report filed with the SEC, except as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our search for a Business Combination, and any
target business with which we may ultimately consummate a Business Combination, may be materially adversely affected by the geopolitical
conditions resulting from the recent invasion of Ukraine by Russia and subsequent sanctions against Russia, Belarus and related individuals
and entities and the status of debt and equity markets, as well as protectionist legislation in our target markets.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">United States and global markets are experiencing
volatility and disruption following the escalation of geopolitical tensions and the recent invasion of Ukraine&#160;by Russia in February
2022. In response to such invasion, the North Atlantic Treaty Organization (&#8220;NATO&#8221;) deployed additional military forces to
eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and
restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions
from the Society for Worldwide Interbank Financial Telecommunication (SWIFT) payment system. Certain countries, including the United States,
have also provided and may continue to provide military aid or other assistance to Ukraine during the ongoing military conflict, increasing
geopolitical tensions with Russia. The invasion of Ukraine by Russia and the resulting measures that have been taken, and could be taken
in the future, by NATO, the United States, the United Kingdom, the European Union and other countries have created global security concerns
that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing military conflict in
Ukraine is highly unpredictable, the conflict could lead to market disruptions, including significant volatility in commodity prices,
credit and capital markets, as well as supply chain interruptions. Additionally, Russian military actions and the resulting sanctions
could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any of the abovementioned factors, or any other negative
impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of&#160;Ukraine and
subsequent sanctions, could adversely affect our search for a Business Combination and any target business with which we may ultimately
consummate a Business Combination. The extent and duration of the Russian invasion of Ukraine, resulting sanctions and any related market
disruptions are impossible to predict, but could be substantial, particularly if current or new sanctions continue for an extended period
of time or if geopolitical tensions result in expanded military operations on a global scale. Any such disruptions may also have the effect
of heightening many of the other risks described in the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K. If these
disruptions or other matters of global concern continue for an extensive period of time, our ability to consummate a Business Combination,
or the operations of a target business with which we&#160;may&#160;ultimately consummate a Business Combination, may be materially adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in laws or regulations, or a failure
to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete a business
combination and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to laws and regulations enacted by
national, regional and local governments. In particular, we will be required to comply with certain SEC and other legal requirements.
Compliance with, and monitoring of, applicable laws and regulations may be difficult, time-consuming and costly. Those laws and regulations
and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our
business, investments, and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted
and applied, could have a material adverse effect on our business, including our ability to negotiate and complete a Business Combination
and results of operations of target business with which we may ultimately consummate a Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 30, 2022, the SEC issued proposed rules (the
&#8220;2022 Proposed Rules&#8221;) relating to, among other items, enhancing disclosures in business combination transactions involving
special purpose acquisition companies (&#8220;SPACs&#8221;) and private operating companies; amending the financial statement requirements
applicable to transactions involving shell companies; effectively limiting the use of projections in SEC filings in connection with proposed
business combination transactions; increasing the potential liability of certain participants in proposed business combination transactions;
and the extent to which SPACs could become subject to regulation under the&#160;Investment Company Act. These rules, if adopted, whether
in the form proposed or in revised form, and certain interpretations expressed by the SEC in connection therewith, may materially adversely
affect our ability to negotiate and complete our initial business combination and may increase the costs and time related thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 17 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_013"></span>Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2022, we consummated the Initial Public
Offering of 8,625,000 Units. The Units were sold at an offering price of $10.00 per unit, generating total gross proceeds of $86,250,000.
EBC and BTIG acted as joint book-running managers of the Initial Public Offering. The securities in the offering were registered under
the Securities Act on registration statement on Form S-1 (No. 333-261788). The SEC declared the registration statements effective on February
8, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simultaneous with the consummation of the Initial
Public Offering, the Sponsor, EBC, and BTIG consummated the private placement of an aggregate of 471,875 Private Units at a price of $10.00
per Private Unit, generating total proceeds of $4,718,750. Each private unit is comprised of one private share and one-half of a warrant.
Each whole private warrant is exercisable to purchase one ordinary share at $11.50. The issuance was made pursuant to the exemption from
registration contained in Section 4(a)(2) of the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Private Warrants are identical to the warrants
underlying the Units sold in the Initial Public Offering, except that the Private Warrants are not transferable, assignable or salable
until after the completion of a Business Combination, subject to certain limited exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Of the gross proceeds received from the Initial Public
Offering, the exercise of the over-allotment option and the Private Units, an aggregate of $87,543,750 was placed in the Trust Account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We paid a total of $1,725,000 in underwriting discounts
and commissions and $206,159 other costs and expenses related to the Initial Public Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For a description of the use of the proceeds generated
in our Initial Public Offering, see Part I, Item 2 of this Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_015"></span>Item 3. Defaults Upon Senior Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_016"></span>Item 4. Mine Safety Disclosures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not Applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_017"></span>Item 5. Other Information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_018"></span>Item 6. Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following exhibits are filed as part of, or incorporated
by reference into, this Quarterly Report on Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; width: 9%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
<td style="padding-bottom: 1pt; width: 1%; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; width: 90%; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Exhibit</b></span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Memorandum and Articles of Association of the Company. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Agreement, dated February 8, 2022, by and between the Company and Continental Stock Transfer &amp; Trust Company, as warrant agent. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000107/e3440_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Unit Certificate. <sup>(2)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000107/e3440_ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Class A Ordinary Share Certificate. <sup>(3)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000107/e3440_ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Warrant Certificate. <sup>(4)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement, dated February 8, 2022, by and among the Company, the Sponsor and the Company&#8217;s officers and directors. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Management Trust Agreement, dated February 8, 2022, by and between the Company and Continental Stock Transfer &amp; Trust Company, as trustee. <sup>(1)</sup></span></a></td></tr>
</table>


<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 20; Value: 17 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
<td style="padding-right: 0.8pt; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement, dated February 8, 2022, by and among the Company, the Sponsor and certain other security holders named therein. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative Services Agreement, dated February 8, 2022, by and between the Company and the Sponsor. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5.1</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex105-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private Units Purchase Agreement, dated February 8, 2022, by and between the Company and the Sponsor. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5.2</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex105-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private Units Purchase Agreement, dated February 8, 2022, by and between the Company and BTIG, LLC. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5.3</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex105-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private Units Purchase Agreement, dated February 8, 2022, by and between the Company and EarlyBirdCapital, Inc. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex10-6.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity Agreement, dated February 8, 2022, between the Company and Paul Conway. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity Agreement, dated February 8, 2022, between the Company and Michael Kalt. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex10-8.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity Agreement, dated February 8, 2022, between the Company and Randy Frankel. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex10-9.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity Agreement, dated February 8, 2022, between the Company and Andrew Friedman. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/0001873964/000173112222000238/e3508_ex10-10.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity Agreement, dated February 8, 2022, between the Company and Julie Uhrman. <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="e3761_ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="e3761_ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="e3761_ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="e3761_ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
XBRL Taxonomy Extension Schema Document</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
<td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 95%; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
filed as an exhibit to our Current Report on Form 8-K filed on February 8, 2022 and incorporated by reference herein.</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
herein by reference to Exhibit 4.1 of the Registrant&#8217;s Registrant Statement on Form S-1 (Registration No. 333-261788) filed with
the SEC on January 27, 2022.</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
herein by reference to Exhibit 4.2 of the Registrant&#8217;s Registrant Statement on Form S-1 (Registration No. 333-261788) filed with
the SEC on January 27, 2022.</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated herein by reference to Exhibit 4.3 of the
Registrant&#8217;s Registrant Statement on Form S-1 (Registration No. 333-261788) filed with the SEC on January 27, 2022. &#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
herewith.</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
herewith.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 21; Value: 17 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_019"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 21.6pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 21.6pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Counter
Press Acquisition Corporation</b></span></td></tr>
<tr style="vertical-align: top">
<td style="width: 50%; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 7%; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="width: 43%; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 13, 2022</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
<td style="border-bottom: Black 1pt solid; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Paul Conway</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Conway</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Executive Officer)</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 13, 2022</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
<td style="border-bottom: Black 1pt solid; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Michael Kalt</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Kalt</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Financial Officer</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Financial and Accounting Officer)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">20</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJy9WN1y2joQfoK8g4bpZU5qkzI9kztDIJNpGnuAtOdW2GtQa0s+kkzCI/Utz0q2+UkwyFycTGYSY+1++/Ptapde77r3ICYsA0n+GU6fyBzyIqMayBRSkMBjwBOjx293BP9OYcmUlpRr+/ggrMjgxr9d4KM9sGYKkjviDT77/ud+n/j9O/+WRN97V+b9SPCUJcA1oxmhPCGRFIVkoKncVBrm9E1wkW8swA+Qigl+R/wbr3r9h/Q9v0+exZq+CvlbkaenUe/q2v5c9R6kKAsDUyotcjLOIEcsVYnufq0psT1zN4UEIKeLDH5SaTxTYxqv6v/HbyBjpszbiZAhh1FGlQplwjgaPFtRCUFzCCLJYghT378ZeN8hX4BEFN/ro8GB14SnASOvNdo1AcRrHgnsEEkqJBEciAUlARE1LlEGmFCNEWwEgBQGnoiUfLIWHHH1o/EqovIHzUrwbjzP8yOQ9uMW64/bgR4UVJK1UUM+VYpIgXSyb4+Y8cJZFWQkg0I6Mb4M0+Ox5Ql+vqJZag98SFWLnRagjmu8xTChORVNJCO+/sugNUflh3S1RTU4DGuLYW3Sw0ulfwJbrjQkwRokXUIlHpZaaXQHfT6S8Vm5+AWxngsTzbzQWF5bJG/QijSkisWYj3uWlQj4DPqRxyKHhjIdkYaji306BLnM9iehVGN5i74TFgZxLMG4E6YjpMUGjbJFtO+p/QBFUJcx7kurskelSspN47j9++vAe+EJyFfJNMiJKM3Dzi7/jKoJZVU1h+mXW78/8LyiXGQsbhobOh6mQZaJGPt7EqbY3w1HhNJO6mc0M5q/+mgn9ro1KrGV9v+rdU+9Y3TdFd6bWxH7wlaTtSnPmTIXlRqhoiUkcxEkCTM8oFlEWfLIR7RgmmYuAXlE7/F6rDPZUlMRMphhYzqsrXNka6w/iKYxcLiZFWi+kNYvvJSNQ0JunoUGpySyJWcpi5FmWB0YWhOXSCD5GKg5vOkh5nEb31F7fCPL2Ma+RvK3k2hFniijsb32OwmPc5BLRMQJ4lXjzZQXlG9mmupSWTc2nbQdj3N3PcfulhMUuABhCjGGKtsEiShM090mb2baLZWJep9FJ7WmRZbv/McOPH4rgKuq0vq+G1f3albdM2Xtc5GfY89TNDZxOd6L9g7gmKC2Y2KHcnepOSymGCCZYE3VNebk/gvGKS4R+rAY3WeDGqzDMIHztHGv6lRPgnInQ9+XXXPbuAOP3+IV5UtsdhXDm7vzbGhDvdo2cne459KcbMAa8J5D839XgLgSpMB0KZ2EI7ox4QnTE1zqzM99XcFSgs1Ah+mTqtW+iqa+cDYybWGrYjjEf81hUu6dJkl93Iz75vxNc2pfJ2mUkp3WU26ctOF0Rj9MTGdzUtWmMsX5Qfgc+7oT/dJSPqxM7EnYkLWLicfa1wTc3Dsqc6YXBEnOuP2GQLM1zMqiEFJfwMs6tFEpsTiVU3nhMmkstZfZblE8spa4+N6MjfbimIL5PgRnuguVnV4/goUJV1zz/Nbz/XYfkee4E2khuwjVI7RdV2psXN2y0uxSe5uM+d5HSHRs/G/J9MbFsXeaq4XQ6HejJsdi4F29abZD2rIdulClbZfdT8uu7bTvgTuadbh8BL9ErGlU230Ix7+D3a7XNqT/B90hBf0= -->
[{"type": "10-Q", "sequence": "1", "filename": "e3761_10-q.htm", "description": "FORM 10-Q", "secsgml_size_bytes": 401157}]
{"company-data": {"conformed-name": "Counter Press Acquisition Corp", "cik": "0001873964", "assigned-sic": "6770", "irs-number": "000000000", "state-of-incorporation": "E9", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "10-Q", "act": "34", "file-number": "001-41274", "film-number": "22922710"}, "business-address": {"street1": "PO BOX 309", "city": "UGLAND HOUSE", "state": "E9", "zip": "KY1-1104", "phone": "917-363-9447"}, "mail-address": {"street1": "1981 MARCUS AVENUE", "street2": "SUITE 227", "city": "LAKE SUCCESS", "state": "NY", "zip": "11042"}}
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark One)
☒
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
March 31, 2022
☐
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to
___________
Commission file number:
001-41274
Counter Press Acquisition Corporation
(Exact name of registrant as specified
in its charter)
Cayman Islands
N/A
(State
or other jurisdiction of
incorporation or organization)
(I.R.S.
Employer
Identification No.)
1981 Marcus Avenue
,
Suite 227
Lake Success
,
NY
11042
(Address of principal executive offices)
(718)
775-3013
(Registrant's telephone number, including
area code)
N/A
(Former name, former address and former
fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of
the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which
registered
Units,
each consisting of one Class A ordinary share and one-half of one redeemable warrant
CPAQU
The
Nasdaq
Stock Market LLC
Class
A ordinary shares, par value $0.0001 per share
CPAQ
The
Nasdaq
Stock Market LLC
Redeemable
warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50
CPAQW
The
Nasdaq
Stock Market LLC
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes
☒
No
☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files).
Yes
☒
No
☐
Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging
growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated
filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
☒
No
☐
As of May 13, 2022, there were
5,102,718
Class
A ordinary shares, $0.0001 par value and
2,156,250
Class B ordinary shares, $0.0001 par value, issued and outstanding.
COUNTER PRESS ACQUISITION CORPORATION
FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2022
TABLE OF CONTENTS
Page
PART I. FINANCIAL INFORMATION
1
Item 1. Financial Statements
1
Unaudited
Condensed Balance Sheets as of March 31, 2022
and December 31, 2021
1
Unaudited
Condensed Statement of Operations for the three months ended March 31, 2022
2
Unaudited
Condensed Statement of Changes in Shareholders' Deficit for the three months ended March 31, 2022
3
Unaudited
Condensed Statement of Cash Flows for the three months ended March 31, 2022
4
Notes to Unaudited Condensed Financial Statements
5
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
14
Item 3. Quantitative and Qualitative Disclosures About Market Risk
16
Item 4. Controls and Procedures
16
PART II. OTHER INFORMATION
17
Item 1. Legal
Proceedings
17
Item 1A. Risk Factors
17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
18
Item 3. Defaults
Upon Senior Securities
18
Item 4. Mine
Safety Disclosures
18
Item 5. Other
Information
18
Item 6. Exhibits
18
PART III. SIGNATURES
20
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
COUNTER PRESS ACQUISITION CORPORATION
CONDENSED BALANCE SHEETS
March 31,   2021
December 31,
2021
(unaudited)
Assets:
Current assets:
Cash
$
645,882
$
—
Prepaid expenses
452,407
—
Due from related party
7,500
—
Total Current Assets
1,105,789
—
Deferred offering costs
—
109,064
Investment held in Trust Account
87,550,251
—
Total Assets
$
88,656,040
$
109,064
Liabilities, Class A Ordinary shares Subject to Possible Redemption, and Shareholders' (Deficit) Equity
Current liabilities:
Accrued offering costs and expenses
$
28,678
$
38,102
Promissory note - related party
—
52,879
Total Current Liabilities
28,678
90,981
Deferred underwriters' discount
3,018,750
—
Total Liabilities
3,047,428
90,981
Commitments and Contingencies (Note 6)
Class A ordinary shares subject to possible redemption,
8,625,000
and no shares at redemption value of $
10.15
per share as of March 31, 2022 and December 31, 2021
87,543,750
—
Shareholders' (Deficit) Equity
Preferred stock, $
0.0001
par value;
1,000,000
shares authorized;
none
issued and outstanding
—
—
Class A ordinary shares, $
0.0001
par value;
200,000,000
shares authorized;
510,625
and
no
shares issued and outstanding (excluding 8,625,000 shares subject to possible redemption) as of March 31, 2022 and December 31, 2021
51
—
Class B ordinary shares, $
0.0001
par value;
20,000,000
shares authorized;
2,156,250
shares issued and outstanding as of March 31, 2022 and December 31, 2021
216
216
Additional paid-in capital
—
24,784
Accumulated deficit
(
1,935,405
)
(
6,917
)
Total shareholders' (deficit) equity
(
1,935,138
)
18,083
Total Liabilities, Class A Ordinary shares Subject to Possible Redemption, and Shareholders' (Deficit) Equity
$
88,656,040
$
109,064
The accompanying notes are an integral part of the
condensed financial statements.
1
COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED STATEMENT OF OPERATIONS
Three Months Ended
March 31,
2022
Operating and formation costs
$
435,263
Loss from operations
(
435,263
)
Other income:
Interest earned on marketable securities held in Trust Account
6,501
Total other income
6,501
Net loss
$
(
428,762
)
Weighted average shares outstanding, Class A ordinary shares subject to redemption
4,600,000
Basic and diluted net income per share, Class A ordinary shares subject to redemption
$
0.55
Weighted average shares outstanding, ordinary shares
2,428,583
Basic and diluted net loss per share, ordinary shares
$
(
1.22
)
The accompanying notes are an integral part of the
unaudited condensed financial statements.
2
COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED STATEMENT OF CHANGES IN SHAREHOLDERS'
DEFICIT
Class A Ordinary Shares
Class B Ordinary Shares
Additional   Paid-in
Accumulated
Total   Shareholders'
Shares
Amount
Shares
Amount
Capital
Deficit
Equity (Deficit)
Balance — January 1, 2022
—
$
—
2,156,250
$
216
$
24,784
$
(
6,917
)
$
18,083
Sale of 471,875 Private Units net of allocated offering costs
471,875
47
—
—
4,718,703
—
4,718,750
Fair value of 4,312,500 Public Warrants net of allocated offering costs
—
—
—
—
1,911,303
—
1,911,303
Issuance of 38,750 Underwriter Founder Shares
38,750
4
—
—
446
—
450
Accretion of carrying value to redemption value
—
—
—
—
(
6,655,236
)
(
1,499,726
)
(
8,154,962
)
Net loss
—
—
—
—
—
(
428,762
)
(
428,762
)
Balance – March 31, 2022
510,625
$
51
2,156,250
$
216
$
—
$
(
1,935,405
)
$
(
1,935,138
)
The accompanying notes are an integral part of the
unaudited condensed financial statements.
3
COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED STATEMENT OF CASH FLOWS
Three Months Ended
March 31,
2022
Cash Flows from Operating Activities:
Net loss
$
(
428,762
)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account
(
6,501
)
Changes in operating assets and liabilities:
Prepaid expenses
(
452,407
)
Accrued expenses
(
9,424
)
Due from related party
(
7,500
)
Net cash used in operating activities
(
904,594
)
Cash Flows from Investing Activities:
Investment held in Trust Account
(
87,543,750
)
Net cash used in investing activities
(
87,543,750
)
Cash Flows from Financing Activities:
Proceeds from sale of Units, net of underwriting discounts paid
84,525,000
Proceeds from sale of Private Units
4,718,750
Issuance of Underwriter Founder Shares
450
Proceeds from issuance of promissory note to related party
25,635
Repayment of promissory note – related party
(
175,609
)
Net cash provided by financing activities
89,094,226
Net Change in Cash
645,882
Cash – Beginning of period
—
Cash – End of period
$
645,882
Non-Cash investing and financing activities:
Deferred underwriting commissions charged to additional paid in capital
$
3,018,750
Deferred offering costs paid by the promissory note
$
97,095
Initial value of ordinary shares subject to possible redemption
$
87,543,750
Accretion of carrying value to redemption value
$
8,154,962
The accompanying notes are an integral part of the
unaudited condensed financial statements.
4
NOTES TO COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2022
NOTE 1.
ORGANIZATION, BUSINESS OPERATIONS
Counter Press Acquisition Corporation (the "Company")
is a blank check company incorporated as a Cayman Islands exempted company on May 19, 2021 whose purpose is to enter into a merger, share
exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar Business Combination with one or more businesses
or entities (the "Business Combination"). The Company has not selected any specific Business Combination target and it has
not (nor has anyone on its behalf), initiated any substantive discussions, directly or indirectly, with any Business Combination target.
As of March 31, 2022, the Company had not commenced
any operations. All activity for the period from May 19, 2021 (inception) through March 31, 2022 relates to the Company's formation,
initial public offering ("Initial Public Offering" or "IPO"), which is described below, and subsequent to the
Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues
until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the
form of interest income on cash and cash equivalents from the proceeds derived from the IPO. The Company has selected December 31 as its
fiscal year end.
The registration statement for the Company's
IPO was declared effective on February 8, 2022 (the "Effective Date"). The Company's sponsor is Counter Press Sponsor
LLC, a Cayman Islands limited liability company (the "Sponsor"). On February 11, 2022, the Company consummated the IPO of
8,625,000
units (including the full exercise of the underwriter's overallotment option of
1,125,000
units) at $
10.00
per unit (the
"Units"), generating gross proceeds of $
86,250,000
, which is discussed in Note 3.
Simultaneously with the closing of the IPO and the
issuance and sale of the Units, the Company consummated in the aggregate, the sale of
471,875
units (the "Private Units")
at a price of $10.00 per Private Unit, to the Sponsor, EarlyBirdCapital, Inc. ("EBC") and BTIG, LLC ("BTIG").
As of February 11, 2022, transaction costs amounted
to $
4,949,909
consisting of $
1,725,000
of underwriting commissions, $
3,018,750
of deferred underwriting commissions and $
206,159
of other
cash offering costs.
The Company must complete one or more initial
Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding taxes
payable on the interest earned on the Trust Account) at the time of signing a definitive agreement in connection with the Business Combination.
The Company will complete the initial Business Combination only if the post-transaction company in which its public shareholders own shares
will own or acquire 50% or more of the issued and outstanding voting securities of the target or is otherwise not required to register
as an investment company under the Investment Company Act (the "Investment Company Act"). There is no assurance that the Company
will be able to complete a Business Combination successfully.
Following the closing of the IPO on February
11, 2022, $
87,543,750
($10.15 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Units was
placed in a Trust Account and, will be held in a U.S.-based trust account ("Trust Account") and will be invested only in U.S.
government treasury bills with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under
the Investment Company Act which invest only in direct U.S. government treasury obligations. Based on current interest rates, the Company
estimates that the interest earned on the Trust Account will be approximately $17,509 per year, assuming no exercise of the underwriters'
overallotment option and an interest rate of 0.02% per year, following the investment of such funds in specified U.S. government treasury
bills or in specified money market funds. Except with respect to the exceptions described below, the proceeds from the IPO and the sale
of the private units will not be released from the Trust Account until the earliest of: (i) the completion of the initial Business Combination;
(ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Company's amended
and restated memorandum and articles of association to (A) modify the substance or timing of the Company's obligation to allow redemption
in connection with the initial Business Combination or to redeem the public shares if the Company does not complete the initial Business
Combination within Combination Period or (B) with respect to any other provision relating to shareholders' rights or pre-Business
Combination activity; and (iii) the redemption of all of the public shares if the Company is unable to complete the initial Business Combination
within Combination Period (as defined below), subject to applicable law. The net proceeds deposited in the Trust Account could become
subject to the claims of the Company's creditors, if any, which could have priority over the claims of its public shareholders.
Therefore, there is no guarantee that investors will receive $10.15 per share upon redemption.
The Company will provide its shareholders
with the opportunity to sell their shares to the Company by means of a tender offer (and thereby avoid the need for a shareholder vote)
for an amount equal to their pro rata share of the aggregate amount then on deposit in the Trust Account (net of amounts required to pay
its income and franchise taxes), in each case subject to the limitations described herein. The decision as to whether the Company will
seek shareholder approval of its proposed Business Combination or allow shareholders to sell their shares to the Company in a tender offer
will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction
and whether the terms of the transaction would otherwise require the Company to seek shareholder approval. If the Company determine to
engage in a tender offer, the Company will file tender offer documents which will contain substantially the same financial and other information
about the initial Business Combination as is required under the SEC's proxy rules.
The Company will provide its public shareholders
with the opportunity to redeem their Class A ordinary shares upon approval of any such amendment at a per-share price, payable in cash,
equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable)
divided by the number of then issued and outstanding public shares.
The ordinary shares subject to redemption
will be recorded at a redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Financial
Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 480 "Distinguishing
Liabilities from Equity."
5
NOTES TO COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2022
The Company will have 12 months from the
closing of the IPO to complete the initial Business Combination (the "Combination Period"), the Company may, at the Sponsor's
option, extend the period of time to consummate a Business Combination up to two times without shareholder approval, each for an additional
three months (for a total of up to 18 months to complete a Business Combination) (each such three-month period, an "Extension Period")
or during any Extension Period. If the Company is unable to complete the initial Business Combination within the Combination Period, the
Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than
ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit
in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $100,000 of interest to pay dissolution
expenses) divided by the number of then issued and outstanding public shares, which redemption will completely extinguish public shareholders'
rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii)
as promptly as reasonably possible following such redemption, subject to the approval of its remaining shareholders and its board of directors,
liquidate and dissolve, subject in each case to the Company's obligations under Cayman Islands law to provide for claims of creditors
and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company's
warrants, which will expire worthless if the Company fails to complete the initial Business Combination within Combination Period.
The Sponsor, officers and directors will
enter into a letter agreement with the Company, pursuant to which they will agree (A) to waive their redemption rights with respect to
their shares in connection with the completion of the initial Business Combination and (B) to waive their rights to liquidating distributions
from the Trust Account with respect to their founders and private shares if the Company fails to complete the initial Business Combination
within Combination Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any public
shares they hold if the Company fails to complete the initial Business Combination within the prescribed time frame), as described herein
and in the Company's amended and restated memorandum and articles of association.
The Sponsor has agreed that it will be liable
to the Company if and to the extent any claims by a third party (other than the Company's independent auditors) for services rendered
or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement,
reduce the amount of funds in the Trust Account to below (i) $10.15 per public share or (ii) such lesser amount per public share held
in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each
case net of the interest which may be withdrawn to pay taxes. This liability will not apply with respect to any claims by a third party
who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company's
indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. Moreover, in the
event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of
any liability for such third party claims. Because the Company is a blank check company, rather than an operating company, and the Company's
operations will be limited to searching for prospective target businesses to acquire, the only third parties the Company currently expect
to engage would be vendors such as lawyers, investment bankers, computer or information and technical services providers or prospective
target businesses.
Liquidity and Capital Resources
In connection with the Company's assessment
of going concern considerations in accordance with Accounting Standards Update ("ASU") 2014-15, "Disclosures of Uncertainties
about an Entity's Ability to Continue as a Going Concern," management believes that the funds which the Company has available
following the completion of the Initial Public Offering will enable it to sustain operations for a period of at least one-year from the
issuance date of this financial statement.
The Company's liquidity needs up to
the closing of the IPO on February 11, 2022 had been satisfied through a payment from the Sponsor of $
25,000
(see Note 5) for the Founder
Shares to cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of $
150,000
(see Note 5). The
promissory note was fully repaid as of the closing of the IPO.
In order to finance transaction costs in
connection with a Business Combination, the Company's Sponsor or an affiliate of the Sponsor or certain of the Company's officers
and directors committed to provide the Company with Working Capital Loans up to $
1,500,000
, as defined later (see Note 5). To date, there
were no amounts outstanding under any Working Capital Loans.
Based on the foregoing, management believes
that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation
of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing
accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective
target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating
and consummating the Business Combination.
Risks and Uncertainties
Management is currently evaluating the impact
of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company's
financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of
the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of
this uncertainty.
NOTE 2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for
interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain
information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or
omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information
and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management,
the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are
necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
6
NOTES TO COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 2022
The accompanying unaudited condensed financial
statements should be read in conjunction with the Company's Current Report on Form 8-K, as filed with the SEC on February 17, 2022.
The interim results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year
ending December 31, 2022 or for any future periods.
Emerging Growth Company
The Company is an "emerging growth company,"
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the "JOBS Act"),
and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and
proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company's financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.
Use of Estimates
The preparation of condensed financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during
the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments with
an original maturity of three months or less when purchased to be cash equivalents.
Investment Held in Trust Account
As of March 31, 2022, the Company had $
87,550,251
in investment held in the Trust Account.
Concentration of Credit Risk
Financial instruments that potentially subject the
Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal
Depository Insurance Corporation limit of $
250,000
. At March 31, 2022, the Company has not experienced losses on this account and management
believes the Company is not exposed to significant risks on such account.
Offering Costs Associated with IPO
Offering costs consist of underwriting, legal, accounting,
registration and other expenses incurred through the balance sheet date that are directly related to the IPO. As of March 31, 2022, offering
costs amounted to $
4,949,909
consisting of $
1,725,000
of underwriting fees, $
3,018,750
of deferred underwriting fees, and $
206,159
of
other offering costs. The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A –
"Expenses of Offering". The Company allocates offering costs between public shares and public warrants based on the
estimated fair values of public shares and public warrants at the date of issuance.
Class A Ordinary Shares Subject to Possible
Redemption
The Company accounts for its ordinary shares subject
to possible redemption in accordance with the guidance in ASC Topic 480 "Distinguishing Liabilities from Equity." Ordinary
shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable
ordinary shares (including ordinary shares that feature redemption rights that is either within the control of the holder or subject to
redemption upon the occurrence of uncertain events not solely within the Company's control) is classified as temporary equity. At
all other times, ordinary shares is classified as shareholders' equity. The Company's ordinary shares features certain redemption
rights that are considered to be outside of the Company's control and subject to occurrence of uncertain future events. Accordingly,
ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders'
equity section of the Company's balance sheets.
7
NOTES TO COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 202
As of March 31, 2022, the Class A ordinary shares
reflected in the balance sheet is reconciled in the following table:
Gross Proceeds
$
86,250,000
Less:
Proceeds allocated to public warrants
(
2,027,672
)
Issuance costs related to Class A ordinary shares
(
4,833,540
)
Plus:
Accretion of carrying value to redemption value
8,154,962
Contingently redeemable Class A ordinary shares
$
87,543,750
Fair Value Measurements
The fair value of the Company's assets and liabilities,
excluding the warrant liability, which qualify as financial instruments under FASB ASC Topic 820, Fair Value Measurement ("ASC 820"),
approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature.
Derivative Financial Instruments
The Company evaluates its financial instruments to
determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815,
"Derivatives and Hedging". The Company's derivative instruments are recorded at fair value on the balance sheets with
changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheet
as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months
of the balance sheet date.
Warrants
The Company accounts for warrants in accordance with
the guidance contained in FASB ASC 815, "Derivatives and Hedging". Under ASC 815-40 warrants that meet the criteria for equity
treatment are recorded in shareholders' equity. The warrants are subject to re-evaluation of the proper classification and accounting
treatment at each reporting period. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability
and remeasured each period with changes recorded in the statement of operations.
Income Taxes
The Company follows the asset and liability method
of accounting for income taxes under FASB ASC 740, "Income Taxes." Deferred tax assets and liabilities are recognized for
the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets
and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances
are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
ASC Topic 740 prescribes a recognition threshold and
a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax
return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.
The Company's management determined that the Cayman Islands is the Company's major tax jurisdiction. The Company recognizes
accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of March 31, 2022 and December 31, 2021,
there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues
under review that could result in significant payments, accruals or material deviation from its position. The Company's management
does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
The Company is considered to be an exempted Cayman
Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing
requirements in the Cayman Islands or the United States. As such, the Company's tax provision was zero for the period presented.
Net Loss per Ordinary Share
The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, "Earnings Per Share". Net income (loss) per ordinary shares is computed by dividing net
income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies the two-class method in
calculating earnings per share. Accretion associated with the redeemable shares of Class A ordinary shares is excluded from earnings per
share as the redemption value approximates fair value.
The calculation of diluted income (loss) per share
does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement
since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase
4,548,438
Class A ordinary shares in the aggregate. As of March 31, 2022, the Company did not have any dilutive securities or other contracts that
could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted
net loss per ordinary shares is the same as basic net loss per ordinary shares for the periods presented.
8
NOTES TO COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 202
The following table reflects the calculation of basic
and diluted net income (loss) per ordinary share (in dollars, except per share amounts):
Three Months Ended   March 31, 2022
Net loss
$
(
428,762
)
Accretion of temporary equity to redemption value
(
8,154,962
)
Net loss including accretion of temporary equity to redemption value
$
(
8,583,724
)
Three Months Ended   March 31, 2022
Redeemable
Non-redeemable
Basic and diluted net loss per share:
Numerator:
Allocation of net loss including accretion of temporary equity
$
(
5,617,794
)
$
(
2,965,930
)
Accretion of temporary equity to redemption value
8,154,962
—
Allocation of net income (loss)
$
2,537,168
$
(
2,965,930
)
Denominator:
Weighted-average shares outstanding
4,600,000
2,428,583
Basic and diluted net income (loss) per share
$
0.55
$
(
1.22
)
Recently Adopted Accounting Standards
In August 2020, the FASB issued ASU 2020-06, Debt-Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40):
Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06"), which simplifies accounting
for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions
that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation
in certain areas. The Company adopted ASU 2020-06 on May 19, 2021 (inception). Adoption of the ASU did not impact the Company's
financial position, results of operations or cash flows.
Recent Accounting Pronouncements
Management does not believe that any recently issued,
but not effective, accounting standards, if currently adopted, would have a material effect on the Company's financial statements.
NOTE 3.
PUBLIC OFFERING
On February 11, 2022, the Company consummated its
IPO of
8,625,000
Units (including the full exercise of the underwriter's overallotment option of
1,125,000
units), at a price of
$
10.00
per Unit, generating gross proceeds to the Company of $
86,250,000
. Each Unit consists of one Class A ordinary share and one-half
of one redeemable warrant (the "Public Warrants"). Each whole warrant entitles the holder to purchase one Class A ordinary
share at a price of $
11.50
per share. Each warrant will become exercisable 30 days after the completion of an initial business combination
and will expire on the fifth anniversary of the Company's completion of an Initial Business Combination or earlier upon redemption
or liquidation.
NOTE 4.
PRIVATE PLACEMENT
Simultaneously with the consummation of the IPO and
the issuance and sale of the Units, the Company consummated in the aggregate
471,875
units (the "Private Units") at a price
of $
10.00
per unit, each comprised of one Class A ordinary share and one-half of a warrant ("Private Warrant"). These private
units will be sold at a price of $
10.00
per unit for gross proceeds of $
4,718,750
. The Sponsor purchased
436,416
of the private units
and BTIG and EBC collectively purchased
35,459
of the private units. Each private unit is comprised of one private share and one-half
of a warrant. A portion of the proceeds from the Private Placement Warrants will be added to the proceeds from the IPO to be held in the
Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the
Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and
the Private Placement Warrants will expire worthless.
9
NOTES TO COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 202
Each private unit is comprised of one private share
and one-half of a warrant. Each whole private warrant is exercisable to purchase one ordinary share at $11.50.
NOTE 5.
RELATED PARTY TRANSACTIONS
Founder Shares
On June 23, 2021, the Sponsor paid $
25,000
, or approximately
$0.012 per share, to cover certain offering costs in consideration for
2,156,250
Class B ordinary shares, par value $
0.0001
(the "Founder
Shares"). Up to
281,250
shares are subject to forfeiture by the Sponsor depending on the extent to which the underwriters'
over-allotment option is exercised. The underwriter founder shares are not subject to forfeiture if the underwriters' over-allotment
option is not exercised.
Subject to customary, minor exceptions, the Company's
Sponsor, as well as its officers and directors, will agree not to transfer, assign or sell any of their founders shares, and to maintain
their founders shares in escrow, until six months after the date of the consummation of our initial business combination (all founder
shares will also be released from escrow and lock-up, if sooner than the above, on the date on which we consummate a liquidation, merger,
amalgamation, share exchange, reorganization or other similar transaction after our initial business combination that results in all of
our shareholders having the right to exchange their ordinary shares for cash, securities or other property).
Subject to customary, minor exceptions, the holders
of the underwriter founder shares will agree not to transfer, assign or sell any such shares without our prior written consent until the
completion of our initial business combination.
Subject to customary, minor exceptions, all of the
holders of private shares will agree not to transfer, assign or sell any of their private shares until the completion of our initial business
combination.
Due from related party
As of March 31, 2022, the Company had $
7,500
of due
from related party, which consisted of $25,000 overpayment to the Sponsor and offset by the accrual of $17,500 of administrative services
fees. As of December 31, 2021, the Company had none of due from related party.
Promissory Note-Related Party
In June 2021, the Sponsor agreed to loan the
Company up to $
150,000
to be used for a
portion of the expenses of the IPO. These loans are non-interest bearing, unsecured and are due at the earlier of February 28, 2022,
or the closing of the IPO. The loan was repaid upon the closing of the IPO out of the offering proceeds not held in the Trust
Account. As of March 31, 2022 and December 31, 2021, nil
and $
52,879
were outstanding under the promissory note, respectively.
Working Capital Loans
In order to finance transaction costs in connection
with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company's officers and directors
may, but are not obligated to, loan the Company funds as may be required ("Working Capital Loans"). If the Company completes
the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to
the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the
initial Business Combination does not close. The Company may use a portion of the working capital held outside the Trust Account to repay
the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $
1,500,000
of
such Working Capital Loans may be convertible into units of the post-Business Combination entity at a price of $
10.00
per unit at the
option of the lender. The units would be identical to the Private Placement Units. As of March 31, 2022 and December 31, 2021, the Company
had no borrowings under the Working Capital Loans.
Office Space, Secretarial and Administrative Services
Commencing on the Effective Date, the Company will
enter into an administrative services agreement pursuant to which it will pay the Sponsor up to $
10,000
per month for office space, administrative
and support services, for up to the 15-month period, which includes the automatic three-month extension period. Upon completion of the
Business Combination or the Company's liquidation, it will cease paying these monthly fees. For the three months ended March 31,
2022, the Company incurred $17,500 in fees for these services , of which such amount offset due from related party.
10
NOTES TO COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 202
NOTE
6.
COMMITMENTS & CONTINGENCIES
Registration Rights
The holders of the founders shares, private units
(including private warrants), Underwriter Founder Shares and warrants that may be issued on conversion of Working Capital Loans (and any
ordinary shares issuable upon the exercise of the private warrants or warrants issued upon conversion of the Working Capital Loans and
upon conversion of the founders shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed
prior to or on the effective date of the IPO requiring the Company to register such securities for resale. The holders of these securities
will be entitled to make up to two demands, excluding short form registration demands, that the Company register such securities. In addition,
the holders have certain "piggyback" registration rights with respect to registration statements filed subsequent to its completion
of the initial Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under
the Securities Act. However, the registration rights agreement provides that the Company will not permit any registration statement filed
under the Securities Act to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred
in connection with the filing of any such registration statements.
Underwriters Agreement
The Company granted the underwriters a 45-day option
from the date of the IPO to purchase up to an additional
1,125,000
units to cover over-allotments, if any, at the IPO price less the underwriting
discounts and commissions. On February 11, 2021, the underwriters fully exercised their over-allotment option to purchase an additional
1,125,000
Units
.
The underwriters were entitled to a cash underwriting
discount of two percent (
2
%) of the gross proceeds of the IPO, or $
1,725,000
. Additionally, the underwriters will be entitled to a deferred
underwriting discount of
3.5
% of the gross proceeds of the IPO upon the completion of the Company's initial Business Combination.
NOTE 7.
SHAREHOLDERS' DEFICIT
Underwriter Founder Shares
In January, prior to the consummation of the IPO,
the Company issued to BTIG and EBC and its designees an aggregate of
38,750
Class A ordinary shares (the "Underwriter Founder Shares")
for generating gross proceeds of $
450
. The Company accounted for the Underwriter Founder Shares as an expense of the IPO, resulting in
a charge directly to Shareholders Equity.
In addition, the holders of the Underwriter Founder
Shares will agree (i) to waive their conversion rights (or right to participate in any tender offer) with respect to such shares in connection
with the completion of our initial business combination and (ii) to waive their rights to liquidating distributions from the trust account
with respect to such shares if we fail to complete our initial business combination within the completion window.
The Underwriter Founder Shares have been deemed compensation
by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the commencement of sales of the public
offering pursuant to Rule 5110(e)(1) of the FINRA Manual. Pursuant to FINRA Rule 5110(e)(1), these securities will not be sold during
the offering, or sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put
or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately
following the commencement of sales of the public offering, except to any underwriter and selected dealer participating in the offering
and their officers or partners, registered persons or affiliates provided that all securities so transferred remain subject to the lockup
restriction above for the remainder of the time period.
Preference shares-
The Company is authorized
to issue
1,000,000
preference shares with a par value of $
0.0001
and with such designations, voting and other rights and preferences as
may be determined from time to time by the Company's board of directors. As of March 31, 2022 and December 31, 2021, there were
no
preference shares issued or outstanding.
Class A ordinary shares-
The Company is authorized
to issue
200,000,000
Class A ordinary shares with a par value of $
0.0001
per share. As of March 31, 2022, there were
510,625
shares issued
and outstanding (excluding 8,625,000 shares subject to possible redemption). As of December 31, 2021, there were
no
Class A ordinary shares
issued and outstanding.
Class B ordinary shares-
The Company is authorized
to issue
20,000,000
Class B ordinary shares with a par value of $
0.0001
per share. Holders are entitled to one vote for each Class B ordinary
share. As of March 31, 2022 and December 31, 2021, there were
2,156,250
Class B ordinary shares issued and outstanding.
Holders of Class A ordinary shares and holders of
Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company's shareholders except
as required by law. Unless specified in the Companies Act, the Company's amended and restated memorandum and articles of association
or applicable stock exchange rules, the affirmative vote of a majority of the Company's ordinary shares that are voted is required
to approve any matter voted on by its shareholders. Approval of certain actions will require a special resolution under Cayman Islands
law and pursuant to the Company's amended and restated memorandum and articles of association; such actions include amending the
Company's amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another
company. Directors are appointed for a term of two years. There is no cumulative voting with respect to the appointment of directors,
with the result that the holders of more than 50% of the Founder Shares purchased prior to the IPO that are voted for the appointment
of directors can appoint all of the directors prior to the initial Business Combination. The Company's shareholders are entitled
to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor.
The Founder Shares will automatically convert into
Class A ordinary shares on the first business day following the completion of the initial Business Combination on a one-for-one basis,
subject to adjustment as provided herein. In the case that additional Class A ordinary shares, or equity-linked securities convertible
or exercisable for Class A ordinary shares, are issued or deemed issued in excess of the amounts issued in the IPO and related to the
closing of the initial Business Combination, the ratio at which founders shares will convert into Class A ordinary shares will be adjusted
(subject to waiver by holders of a majority of the Class B ordinary shares then in issue) so that the number of Class A ordinary shares
issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of its
ordinary shares issued and outstanding upon the completion of the IPO plus the number of Class A ordinary shares and equity-linked securities
issued or deemed issued in connection with the initial Business Combination (net of redemptions), (excluding the underwriter founder shares
and the private shares).
11
NOTES TO COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 202
Public Warrants
— As of March 31, 2022,
there were
4,312,500
Public Warrants outstanding. As of December 31, 2021, there were no Public Warrants outstanding. Each whole warrant
entitles the holder to purchase one Class A ordinary share at a price of $
11.50
per share, subject to adjustment. The warrants will become
exercisable 30 days following the completion of the Business Combination. The warrants will expire at 5:00 p.m., New York City time, five
years after the completion of the Business Combination, or earlier upon redemption.
In addition, if (x) the Company issue additional Class
A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination
at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price
to be determined in good faith by its board of directors, and in the case of any such issuance to the Sponsor, initial shareholders or
their affiliates, without taking into account any founders shares held by them prior to such issuance) (which the Company refer to as
the "Newly Issued Price"), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity
proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial
Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the
20 trading day period starting on the trading day prior to the day on which the Company consummate the initial Business Combination (such
price, the "Market Value") is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest
cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the Newly Issued Price and the $18.00 per share redemption trigger
price described below under "Redemption of warrants" will be adjusted (to the nearest cent) to be equal to 180% of the greater
of (i) the Market Value or (ii) the Newly Issued Price.
No warrants will be exercisable for cash unless the
registration statement of which this prospectus forms a part (or a different registration statement covering the Class A ordinary shares
issuable upon exercise of the warrants) is then in effect and this prospectus (or such other prospectus that is part of such other registration
statement) is then current. Notwithstanding the foregoing, if a registration statement covering the Class A ordinary shares issuable upon
exercise of the warrants is not then in effect during the period beginning 60 business days following the consummation of the initial
Business Combination, warrant holders may, during any period when the Company shall have failed to maintain an effective registration
statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933,
as amended, or the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available,
holders will not be able to exercise their warrants on a cashless basis.
Redemption of warrants. Once the warrants become
exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):
●
in whole and not in part;
●
at a price of $
0.01
per warrant;
●
upon a minimum of 30 days' prior written notice of redemption (the "Redemption Period")
●
if, and only if, the last sale price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share consolidations, share capitalizations, rights issuances, reorganizations, recapitalizations and the like, or as described above under "Exercise price of warrants") for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending on the third trading day prior to the date on which the Company send the notice of redemption to the warrant holders; and
●
there is a current registration statement in effect with respect to the Class A ordinary shares underlying such warrants.
Private Placement Warrants
- At March 31, 2022,
there were
235,938
Private Placement Warrants outstanding. As of December 31, 2021, there were
no
Private Placement Warrants outstanding.
The private warrants are identical to the warrants sold as part of the units in this offering except that, so long as they are held by
our sponsor or its permitted transferees: (1) they (including the ordinary shares issuable upon exercise of these warrants) may not, subject
to certain limited exceptions, be transferred, assigned or sold by our sponsor until 30 days after the completion of our initial business
combination; and (2) they (including the ordinary shares issuable upon exercise of these warrants) are entitled to registration rights.
NOTE 8.
FAIR VALUE MEASUREMENTS
The fair value of the Company's financial assets
and liabilities reflects management's estimate of amounts that the Company would have received in connection with the sale of the
assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement
date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs
(market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market
participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based
on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
12
NOTES TO COUNTER PRESS ACQUISITION CORPORATION
UNAUDITED CONDENSED FINANCIAL STATEMENTS
MARCH 31, 202
Level 1:
Quoted prices in
active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for
the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs
other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted
prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable
    inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
At March 31, 2022, investment held in the Trust Account
were comprised of $
87,550,251
in money market funds which are invested primarily in U.S. Treasury Securities. Through March 31, 2022,
the Company withdrew $
6,501
of interest earned on the Trust Account.
The following table presents information about the
Company's assets that are measured at fair value on a recurring basis at March 31, 2022 and indicates the fair value hierarchy of
the valuation inputs the Company utilized to determine such fair value:
Description
Level
March 31, 2022
Assets:
Investments held in Trust Account – U.S. Treasury Securities Money Market Fund
1
$
87,550,251
NOTE 9.
SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review,
the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.
13
Item 2. Management's Discussion and Analysis
of Financial Condition and Results of Operations.
References in this report (the "Quarterly Report")
to "we," "us" or the "Company" refer to Counter Press Acquisition Corporation, references to our "management"
or our "management team" refer to our officers and directors, and references to the "Sponsor" refer to Counter
Press Sponsor LLC. The following discussion and analysis of the Company's financial condition and results of operations should be
read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information
contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Special Note Regarding Forward-Looking Statements
This Quarterly Report includes "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act that are not historical
facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All
statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this
"Management's Discussion and Analysis of Financial Condition and Results of Operations" regarding the completion of
the Proposed Business Combination (as defined below), the Company's financial position, business strategy and the plans and objectives
of management for future operations, are forward-looking statements. Words such as "expect," "believe," "anticipate,"
"intend," "estimate," "seek" and variations and similar words and expressions are intended to identify
such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management's
current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ
materially from the events, performance and results discussed in the forward-looking statements, including that the conditions of the
Proposed Business Combination are not satisfied. For information identifying important factors that could cause actual results to differ
materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company's final
prospectus for its Initial Public Offering filed with the U.S. Securities and Exchange Commission (the "SEC"). The Company's
securities filings can be accessed on the EDGAR section of the SEC's website at www.sec.gov. Except as expressly required by applicable
securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result
of new information, future events or otherwise.
Overview
We are a blank check company incorporated as a Cayman
Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses. We have not selected any specific business combination target and we have
not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target.
We intend to effectuate our initial business combination using cash from the net proceeds of our initial public offering and a portion
of the private placement of the private units, our shares, debt or a combination of cash, shares and debt.
The issuance of additional ordinary shares in a business
combination:
●
may significantly dilute the equity interest of investors in our initial public offering,
which dilution would increase if the anti-dilution provisions of the Class B ordinary shares resulted in the issuance of Class A ordinary
shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares;
●
may subordinate the rights of holders of Class A ordinary shares if preferred shares are
issued with rights senior to those afforded our Class A ordinary shares;
●
could cause a change of control if a substantial number of our ordinary shares are issued,
which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation
or removal of our present officers and directors;
●
may have the effect of delaying or preventing a change of control of us by diluting the share
ownership or voting rights of a person seeking to obtain control of us; and
●
may adversely affect prevailing market prices for our Class A ordinary shares and/or warrants.
Similarly, if we issue debt securities or otherwise
incur significant indebtedness, it could result in:
●
default and foreclosure on our assets if our operating revenues after an initial business
combination are insufficient to repay our debt obligations;
●
acceleration of our obligations to repay the indebtedness even if we make all principal and
interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without
a waiver or renegotiation of that covenant;
●
our immediate payment of all principal and accrued interest, if any, if the debt security
is payable on demand;
●
our inability to obtain necessary additional financing if the debt security contains covenants
restricting our ability to obtain such financing while the debt security is issued and outstanding;
●
our inability to pay dividends on our ordinary shares;
14
●
using a substantial portion of our cash flow to pay principal and interest on our debt, which
will reduce the funds available for dividends on our ordinary shares if declared, expenses, capital expenditures, acquisitions and other
general corporate purposes;
●
limitations on our flexibility in planning for and reacting to changes in our business and
in the industry in which we operate;
●
increased vulnerability to adverse changes in general economic, industry and competitive
conditions and adverse changes in government regulation; and
●
limitations on our ability to borrow additional amounts for expenses, capital expenditures,
acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors
who have less debt.
Although we raised $86,250,000 of gross
proceeds, in the aggregate, from our initial public offering in February 2022, and additional $4,718,750 of gross proceeds, in the aggregate,
from our private placements consummated concurrently with the closing of our initial public offering, we expect to continue to incur significant
costs in the pursuit of our acquisition plans. We cannot assure you that our plans to raise capital or to complete our initial business
combination will be successful.
Results of Operations
We have neither engaged in any operations nor generated
any revenues to date. Our only activities from February 11, 2022 (inception) through March 31, 2022 were organizational activities, those
necessary to prepare for the Initial Public Offering, described below, and identifying a target company for a Business Combination. We
do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income
in the form of interest income on marketable securities held in the Trust Account. We incur expenses as a result of being a public company
(for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.
For the three months ended March 31, 2022, we had
a net loss of $428,762, which consists of operating costs of $435,263 and offset by interest income on investment held in the Trust Account
of $6,501.
Liquidity and Capital Resources
On February 11, 2022, we consummated the IPO of 8,625,000
Units at $10.00 per Unit, generating gross proceeds of $86,250,000. Simultaneously with the closing of the IPO and the issuance and sale
of the Units, we consummated in the aggregate, the sale of 471,875 Private Units at a price of $10.00 per Private Unit, to the Sponsor,
EBC and BTIG.
Following the Initial Public Offering, and the sale
of the Private Units, a total of $87,543,750 was placed in the Trust Account. We incurred $4,949,909 in Initial Public Offering related
costs, including $1,725,000 of underwriting commissions, $3,018,750 of deferred underwriting commissions and $206,159 of other cash offering
costs.
For the three months ended March 31, 2022, cash used
in operating activities was $904,594. Net loss of $428,762 was affected by interest earned on investment held in the Trust Account of
$6,501, and changes in operating assets and liabilities of $469,331.
In connection with the Company's assessment
of going concern considerations in accordance with Accounting Standards Update ("ASU") 2014-15, "Disclosures of Uncertainties
about an Entity's Ability to Continue as a Going Concern," management believes that the funds which the Company has available
following the completion of the Initial Public Offering will enable it to sustain operations for a period of at least one-year from the
issuance date of this financial statement.
The Company's liquidity needs up to the closing
of the IPO on February 11, 2022 had been satisfied through a payment from the Sponsor of $25,000 (see Note 5) for the Founder Shares to
cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of $150,000. The promissory note was fully
repaid as of the closing of the IPO.
In order to finance transaction costs in connection
with a Business Combination, the Company's Sponsor or an affiliate of the Sponsor or certain of the Company's officers and
directors committed to provide the Company with Working Capital Loans up to $1,500,000, as defined later (see Note 5). To date, there
were no amounts outstanding under any Working Capital Loans.
Off-Balance Sheet Arrangements
We have no obligations, assets or liabilities, which
would be considered off-balance sheet arrangements as of March 31, 2022. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.
Contractual obligations
We do not have any long-term debt, capital lease obligations,
operating lease obligations or long-term liabilities, other than an agreement to pay the Sponsor up to $10,000 per month for office space,
administrative and support services, for up to the 15-month period, which includes the automatic three-month extension period. We began
incurring these fees on February 8, 2022 and will continue to incur these fees monthly until the earlier of the completion of the Business
Combination and our liquidation.
15
The underwriters are entitled to a cash
underwriting discount of two percent (2%) of the gross proceeds of the IPO, or $1,725,000. Additionally, the underwriters will be entitled
to a deferred underwriting discount of 3.5% of the gross proceeds of the IPO upon the completion of the Company's initial Business
Combination.
Critical Accounting Policies
The preparation of condensed financial statements
and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities
at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from
those estimates. We have identified the following critical accounting policies:
Class A Ordinary Shares Subject to Possible Redemption
We account for our ordinary shares subject to possible
conversion in accordance with the guidance in Accounting Standards Codification ("ASC") Topic 480 "Distinguishing Liabilities
from Equity." Ordinary shares subject to mandatory redemption are classified as a liability instrument and measured at fair value.
Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control
of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary
equity. At all other times, ordinary shares are classified as shareholders' equity. Our ordinary shares feature certain redemption
rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, ordinary shares
subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders' equity section
of our condensed balance sheets.
Net Loss Per Ordinary Share
We comply with accounting and disclosure requirements
of FASB ASC Topic 260, "Earnings Per Share". Net income (loss) per ordinary shares is computed by dividing net income (loss)
by the weighted average number of ordinary shares outstanding for the period. We apply the two-class method in calculating earnings per
share. Accretion associated with the redeemable shares of Class A ordinary shares is excluded from earnings per share as the redemption
value approximates fair value.
The calculation of diluted income (loss) per share
does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement
since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 4,548,438
Class A ordinary shares in the aggregate. As of March 31, 2022, we did not have any dilutive securities or other contracts that could,
potentially, be exercised or converted into ordinary shares and then share in our earnings. As a result, diluted net loss per ordinary
shares is the same as basic net loss per ordinary shares for the periods presented.
Recent Accounting Standards
In August 2020, the FASB issued ASU 2020-06, Debt-Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40):
Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06"), which simplifies accounting
for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions
that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation
in certain areas. We adopted ASU 2020-06 on May 19, 2021 (inception). Adoption of the ASU did not impact our financial position, results
of operations or cash flows.
Item 3. Quantitative and Qualitative Disclosures
About Market Risk.
We are a smaller reporting company as defined by Rule
12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Disclosure controls are procedures that are designed
with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Form
10-Q, is recorded, processed, summarized, and reported within the time period specified in the SEC's rules and forms. Disclosure
controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including
the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management
evaluated, with the participation of our current chief executive officer and chief financial officer (our "Certifying Officers"),
the effectiveness of our disclosure controls and procedures as of March 31, 2022, pursuant to Rule 13a-15(b) or Rule 15d-15(b) under the
Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of March 31, 2022 our disclosure controls and procedures
were effective.
We do not expect that our disclosure controls and
procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the
design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered
relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls
and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design
of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can
be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that
occurred during the fiscal quarter ended March 31, 2022 covered by this Quarterly Report on Form 10-Q that has materially affected, or
is reasonably likely to materially affect, our internal control over financial reporting.
16
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
None.
Item 1A. Risk Factors.
Factors that could cause our actual results to differ
materially from those in this report include the risk factors described in our Annual Report on Form 10-K for the year ended December
31, 2021 filed with the SEC on March 31, 2022. As of the date of this Form 10-Q, there have been no material changes to the risk factors
disclosed in our Annual Report filed with the SEC, except as described below.
Our search for a Business Combination, and any
target business with which we may ultimately consummate a Business Combination, may be materially adversely affected by the geopolitical
conditions resulting from the recent invasion of Ukraine by Russia and subsequent sanctions against Russia, Belarus and related individuals
and entities and the status of debt and equity markets, as well as protectionist legislation in our target markets.
United States and global markets are experiencing
volatility and disruption following the escalation of geopolitical tensions and the recent invasion of Ukraine by Russia in February
2022. In response to such invasion, the North Atlantic Treaty Organization ("NATO") deployed additional military forces to
eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and
restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions
from the Society for Worldwide Interbank Financial Telecommunication (SWIFT) payment system. Certain countries, including the United States,
have also provided and may continue to provide military aid or other assistance to Ukraine during the ongoing military conflict, increasing
geopolitical tensions with Russia. The invasion of Ukraine by Russia and the resulting measures that have been taken, and could be taken
in the future, by NATO, the United States, the United Kingdom, the European Union and other countries have created global security concerns
that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing military conflict in
Ukraine is highly unpredictable, the conflict could lead to market disruptions, including significant volatility in commodity prices,
credit and capital markets, as well as supply chain interruptions. Additionally, Russian military actions and the resulting sanctions
could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.
Any of the abovementioned factors, or any other negative
impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine and
subsequent sanctions, could adversely affect our search for a Business Combination and any target business with which we may ultimately
consummate a Business Combination. The extent and duration of the Russian invasion of Ukraine, resulting sanctions and any related market
disruptions are impossible to predict, but could be substantial, particularly if current or new sanctions continue for an extended period
of time or if geopolitical tensions result in expanded military operations on a global scale. Any such disruptions may also have the effect
of heightening many of the other risks described in the "Risk Factors" section of our Annual Report on Form 10-K. If these
disruptions or other matters of global concern continue for an extensive period of time, our ability to consummate a Business Combination,
or the operations of a target business with which we may ultimately consummate a Business Combination, may be materially adversely
affected.
Changes in laws or regulations, or a failure
to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete a business
combination and results of operations.
We are subject to laws and regulations enacted by
national, regional and local governments. In particular, we will be required to comply with certain SEC and other legal requirements.
Compliance with, and monitoring of, applicable laws and regulations may be difficult, time-consuming and costly. Those laws and regulations
and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our
business, investments, and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted
and applied, could have a material adverse effect on our business, including our ability to negotiate and complete a Business Combination
and results of operations of target business with which we may ultimately consummate a Business Combination.
On March 30, 2022, the SEC issued proposed rules (the
"2022 Proposed Rules") relating to, among other items, enhancing disclosures in business combination transactions involving
special purpose acquisition companies ("SPACs") and private operating companies; amending the financial statement requirements
applicable to transactions involving shell companies; effectively limiting the use of projections in SEC filings in connection with proposed
business combination transactions; increasing the potential liability of certain participants in proposed business combination transactions;
and the extent to which SPACs could become subject to regulation under the Investment Company Act. These rules, if adopted, whether
in the form proposed or in revised form, and certain interpretations expressed by the SEC in connection therewith, may materially adversely
affect our ability to negotiate and complete our initial business combination and may increase the costs and time related thereto.
17
Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds.
On February 11, 2022, we consummated the Initial Public
Offering of 8,625,000 Units. The Units were sold at an offering price of $10.00 per unit, generating total gross proceeds of $86,250,000.
EBC and BTIG acted as joint book-running managers of the Initial Public Offering. The securities in the offering were registered under
the Securities Act on registration statement on Form S-1 (No. 333-261788). The SEC declared the registration statements effective on February
8, 2021.
Simultaneous with the consummation of the Initial
Public Offering, the Sponsor, EBC, and BTIG consummated the private placement of an aggregate of 471,875 Private Units at a price of $10.00
per Private Unit, generating total proceeds of $4,718,750. Each private unit is comprised of one private share and one-half of a warrant.
Each whole private warrant is exercisable to purchase one ordinary share at $11.50. The issuance was made pursuant to the exemption from
registration contained in Section 4(a)(2) of the Securities Act.
The Private Warrants are identical to the warrants
underlying the Units sold in the Initial Public Offering, except that the Private Warrants are not transferable, assignable or salable
until after the completion of a Business Combination, subject to certain limited exceptions.
Of the gross proceeds received from the Initial Public
Offering, the exercise of the over-allotment option and the Private Units, an aggregate of $87,543,750 was placed in the Trust Account.
We paid a total of $1,725,000 in underwriting discounts
and commissions and $206,159 other costs and expenses related to the Initial Public Offering.
For a description of the use of the proceeds generated
in our Initial Public Offering, see Part I, Item 2 of this Form 10-Q.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not Applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
The following exhibits are filed as part of, or incorporated
by reference into, this Quarterly Report on Form 10-Q.
No.
Description of Exhibit
3.1
Amended and Restated Memorandum and Articles of Association of the Company.
(1)
4.1
Warrant Agreement, dated February 8, 2022, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent.
(1)
4.2
Specimen Unit Certificate.
(2)
4.3
Specimen Class A Ordinary Share Certificate.
(3)
4.4
Specimen Warrant Certificate.
(4)
10.1
Letter Agreement, dated February 8, 2022, by and among the Company, the Sponsor and the Company's officers and directors.
(1)
10.2
Investment Management Trust Agreement, dated February 8, 2022, by and between the Company and Continental Stock Transfer & Trust Company, as trustee.
(1)
18
10.3
Registration Rights Agreement, dated February 8, 2022, by and among the Company, the Sponsor and certain other security holders named therein.
(1)
10.4
Administrative Services Agreement, dated February 8, 2022, by and between the Company and the Sponsor.
(1)
10.5.1
Private Units Purchase Agreement, dated February 8, 2022, by and between the Company and the Sponsor.
(1)
10.5.2
Private Units Purchase Agreement, dated February 8, 2022, by and between the Company and BTIG, LLC.
(1)
10.5.3
Private Units Purchase Agreement, dated February 8, 2022, by and between the Company and EarlyBirdCapital, Inc.
(1)
10.6
Indemnity Agreement, dated February 8, 2022, between the Company and Paul Conway.
(1)
10.7
Indemnity Agreement, dated February 8, 2022, between the Company and Michael Kalt.
(1)
10.8
Indemnity Agreement, dated February 8, 2022, between the Company and Randy Frankel.
(1)
10.9
Indemnity Agreement, dated February 8, 2022, between the Company and Andrew Friedman.
(1)
10.10
Indemnity Agreement, dated February 8, 2022, between the Company and Julie Uhrman.
(1)
31.1*
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*
Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*
Inline XBRL Instance Document
101.SCH*
Inline
XBRL Taxonomy Extension Schema Document
101.CAL*
Inline
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
Inline
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*
Inline
XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*
Inline
XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
(1)
Previously
filed as an exhibit to our Current Report on Form 8-K filed on February 8, 2022 and incorporated by reference herein.
(2)
Incorporated
herein by reference to Exhibit 4.1 of the Registrant's Registrant Statement on Form S-1 (Registration No. 333-261788) filed with
the SEC on January 27, 2022.
(3)
Incorporated
herein by reference to Exhibit 4.2 of the Registrant's Registrant Statement on Form S-1 (Registration No. 333-261788) filed with
the SEC on January 27, 2022.
(4)
Incorporated herein by reference to Exhibit 4.3 of the
Registrant's Registrant Statement on Form S-1 (Registration No. 333-261788) filed with the SEC on January 27, 2022.
*
Filed
herewith.
**
Furnished
herewith.
19
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Counter
Press Acquisition Corporation
Date:
May 13, 2022
By:
/s/
Paul Conway
Name:
Paul
Conway
Title:
Chief
Executive Officer
(Principal
Executive Officer)
Date:
May 13, 2022
By:
/s/
Michael Kalt
Name:
Michael
Kalt
Title:
Chief
Financial Officer
(Principal
Financial and Accounting Officer)
20